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SUMMARY 
 
Steatosis of the liver is defined by an excess accumulation of intracellular triglycerides within the hepatocytes. 
Nonalcoholic fatty liver disease ranges from simple steatosis to nonalcoholic steatohepatitis. It is a serious 
health problem worldwide, reported to affect 15 – 30 % of the population in developed countries. Inordinate 
accumulation of fat is damaging to the liver, because high levels of triglycerides, free fatty acids, or 
intermediates of lipid metabolism are extremely problematic for a cell. A further problem is that nonalcoholic 
fatty liver disease can be a risk factor for developing adverse reactions to drugs, interfering with hepatic lipid 
metabolism, leading to idiosyncratic drug-induced liver injury. Drug-induced liver injury has been the major 
cause of drugs failing market-approval or for later withdrawal from the market. An improved preclinical 
detectability of such adverse reactions would therefore be highly appreciated by the industry, as well as by 
patients. 
The present work consists of three projects investigating molecular mechanisms of drug-induced hepatic 
steatosis in vitro, and is emphasizing on the application of an optimized method to measure the acylcarnitine 
pattern of cells, treated with toxicants. We focused on the measurement of acylcarnitines, because they are 
known to reflect the cellular acyl-CoA pattern, allowing us to make interpretations on the specific location of 
inhibition by a substance. Furthermore, the liquid chromatography-tandem mass spectrometry method, used 
for this determination, allows for a fast and economic workup and analysis of a high number of samples, 
applicable for high-throughput screenings. Additionally, the small sample volume needed for the analysis 
allows this assay to be linked together with many other 96-well format assays. An important finding in our 
study was that the acylcarnitine method repeatedly turned out to be a more sensitive approach to identify drugs 
inhibiting fatty acid oxidation, as the older, well-established methods, such as radio-enzymatic determination 
of β-oxidation inhibition, or lipid accumulation experiments.  
In the first paper, we aimed to establish and optimize the semi-quantitative acylcarnitine measurement with 
three specific and well-characterized inhibitors of fatty acid oxidation. We compared, as well as supplemented, 
the results of the new method with older, well-established methods. In a second step of the study, we applied 
the same methods on three compounds, of which adverse reactions are not well understood, to obtain new 
insights about their steatogenic mechanisms. 
In the two following papers, investigating the catechol-O-methyl-transferase inhibitors tolcapone and 
entacapone, we aimed to expand the knowledge of tolcapone-associated steatosis and liver toxicity observed 
in clinics. Entacapone was included as well, because of its structural similarity. We studied in detail effects on 
lipid metabolism, as well as on their actions on mitochondrial respiration and cell death, for a comprehensive 
toxicological study about the two drugs.  
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An accumulation of effects are compiled in the following graphical abstract (Fig. 1). 
 
  
Fig. 1. Graphical abstract. Shown are the cumulated effects linked to the induction of hepatic steatosis of the substances used 
in this thesis from our own investigations as well as from literature. Negative effects can be upregulation of FA uptake, 
upregulation of lipid synthesis, decrease in FA breakdown, or decrease in lipid excretion. Furthermore, disruption of oxphos 
and cytotoxic potential on our cell models are displayed. Effects on ATP production, as well as lipid accumulation, both from
measurements of our studies, may be secondary responses to effects of upstream processes. Negative effect (●) intensities are 
interpreted as overall relations of a compounds effects, such as lipid accumulation vs. cytotoxicity, or β-oxidation inhibition vs. 
lipid accumulation, and may therefore seem subjective. Furthermore, these intensities are chosen in relation to each other, 
neglecting substances outside the thesis. Missing connections indicate the lack of measurements or the lack in literature, 
incorporated in this thesis. Abbreviations: FA: fatty acid, Lip. Prot.: lipoprotein, VLDL: very-low densitiy lipoprotein, LD: 
lipid droplet, BC: bile canaliculus, oxphos: oxidative phosphorylation, ATP: adenosine triphosphate, ER: endoplasmic 
reticulum, LPL: lipoprotein lipase, HLP: hormone sensitive lipase. 
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1. INTRODUCTION 
 
1.1 Fat 
This thesis is revolved around lipids. Fat, oil, lard, dripping, butter, blubber, schmaltz, lard, ghee, grease, smen, 
or any other form or name it appears in our diet or physiology, they practically accompany us and every other 
animal throughout our life. 
Essentially, fats (solid at room temperature) and oils (liquid at room temperature) are mainly composed of fatty 
acids (FAs) and glycerol linked by an ester bond, so called triglycerides (TGs) (Fig. 2). Lipids, however, are 
not only TGs. They are defined as any class of organic compounds that are insoluble in water 4. In our diet the 
predominant dietary lipids are TGs, phospholipids, and cholesterol 5. They provide 30 – 40 % of our total food 
energy intake 6,7, which is not surprising, as fat has the highest energy density (kcal/g) of all foods. As 
comparison, pure sugar has approximately half of the calories per gram than olive oil 8.  
 
 
 
 
 
 
The main bulk of energy originates from FAs, which derive from lipids through efficient breakdown, as 
discussed in detail in further sections. FAs are not only weighty regarding calories, but they also have many 
other functions in our bodies. They are first and foremost integral components of all cellular membranes. They 
affect signal transductions and protein binding 9 and also act as precursors for hormones and substrates in 
signaling pathways 10. Therefore, it is unsurprising that the body has to tightly regulate the metabolism of such 
biologically important substances. 
Fig. 2. Nomenclature and chemical structures of fatty acids, triglycerides and relevant precursors. 
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1.1.1 Digestion and Uptake 
Lipid absorption and subsequent systemic distribution, as well as storage, have been extensively investigated 
early on 7,11,12. Currently, numerous articles are published on the topic, giving a more comprehensive overview 
over the fate of dietary lipids 3,5,10,13. As they are water insoluble compounds, they have to be markedly altered 
prior to uptake. Fat absorption requires a complex series of events involving gastric, intestinal, biliary, and 
pancreatic functions 7.  
Already the first contact with our body, when long-chain FAs come in contact with our tongue, prepares the 
digestive system for lipid intake. The FA transporter CD36 is expressed on the taste buds of the tongue, leading 
to a cephalic response, in order to prepare the gastrointestinal tract for optimal absorption. These FA-sensing 
receptors are expressed throughout the upper gastro intestinal tract, as well as in numerous other tissues. The 
actual digestion of TGs starts also in the mouth and stomach, where a lingual lipase and gastric lipase are 
expressed and secreted.  
Lipases are the main enzymes responsible for making lipids suitable for uptake. They hydrolyze the ester bonds 
of two acyl-chains of a TG to yield free FAs and monoacyl glycerol. The main share of lipase action on dietary 
lipids, however, is done by the pancreatic lipase. Bile acids, originating from the liver, have a central role in 
the digestion of lipids as well. They help to form micelles that disperse the water-insoluble lipids and make 
them more available for protein-digestion as well as for uptake by enterocytes in the small intestine. Free FAs, 
monoacyl glycerols, free cholesterol, cholesterol esters, plant sterols, and phospholipids, upon uptake by the 
enterocyte, are either degraded for resynthetization or directly packed into lipid droplets (LDs) at the apical 
side of the cells for further use.  
1.1.2 Distribution and Storage 
The lipids within the enterocytes are eventually excreted to the lymph over complex mechanisms. This export 
starts with the synthesis of apolipoprotein B48 (ApoB48), which is rapidly loaded with TGs. After initial lipid 
loading, membrane formation with free cholesterol and phospholipids occurs, following a secondary core 
expansion with more TGs and cholesteryl esters. After subsequent budding from the endoplasmic reticulum 
(ER), this early form of a chylomicron fuses with the Golgi, where this vesicle undergoes further modifications, 
such as addition of other lipoproteins and protein glycosylation. Mature chylomicrons are finally released from 
the basolateral side via exocytosis and enter the circulation at the thoracic duct (Fig. 3).  
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Fig. 3. Schematic representation of intestinal lipoprotein assembly. In a first step, the nascent ApoB48 polypeptide 
is co-translationally translocated across the rough ER membrane (1). When lipids are available within the ER 
membrane, physical interactions between ApoB48 and MTTP promote optimal folding and biogenesis of a 
primordial lipoprotein particle (1a). MTTP resides as a heterodimeric complex with the chaperone protein PDI. 
MTTP also promotes mobilization of TG-rich lipid droplets from the smooth ER membrane into the lumen of the 
ER, to emerge as luminal lipid droplets (2). When TG availability is limited or MTTP function is impaired, nascent 
ApoB becomes misfolded and is degraded (1b). During the second step of lipoprotein assembly, the primordial 
particle fuses with luminal lipid droplets, resulting in a core expansion, which gives so called pre-chylomicron 
transport vesicles (PCTVs) (3). Other proteins, including CD36 and L-FABP, participate in the TG loading of 
PCTV as well. After fusion with vesicular transport proteins, like COP II, the pre-chylomicron particles are 
incorporated into a vesicular complex that buds from the ER and fuses with the Golgi apparatus. Vectorial 
transport of these pre-chylomicron particles (4) results in their continued maturation by the addition of further 
proteins and glycosylation. Eventually, mature chylomicron particles are secreted into the lymphatic capillaries 
(5). The scheme is adapted from Abumrand and Davidson 3. Abbreviations: Apo: apolipoprotein, CD36: fatty acid 
translocase / cluster of differentiation 36, CE: cholesterol ester, COP II: coat protein 2, ER: endoplasmic reticulum, 
ERAD: ER-associated degradation pathways, L-FABP: fatty acid binding protein 1, MTTP: microsomal 
triglyceride transfer protein, PCTV: pre-chylomicron transport vesicle, PDI: protein disulfide isomerase, TG: 
triglyceride. 
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The synthesis, maturation and excretion of chylomicrons is very similar to the pathway of hepatocytes 
excreting TGs, using very-low-density lipoprotein (VLDL), which is discussed in more detail below. 
Chylomicrons, as VLDL, are lipoproteins in the circulation for the purpose of distributing energy-rich TGs to 
different tissues. As explained above, chylomicrons originate from the intestine and VLDL from the liver, two 
tissues with highly active lipid metabolism. A key player of lipoprotein metabolism is the lipoprotein lipase 
(LPL), which is synthesized in skeletal muscle, heart, and adipose tissue 14. After export from the 
aforementioned tissues, the LPL is attached to the endothelium of adjacent blood capillaries. LPL binds to 
circulating lipoproteins and hydrolyzes the TGs, they carry in their cores, into FAs. These are then taken up 
by the cells through fatty acid transport proteins (FATPs), like for example by the CD36 transporter.  
During the loss of about 50% of lipids from the core of chylomicrons or VLDL vesicles, a series of specific 
apolipoprotein exchanges take place, as well as the enrichment of cholesteryl esters. One important lipoprotein 
exchange is the acquisition of ApoE, originating from the interaction with high-density lipoprotein (HDL). 
These changes lead chylomicrons and VLDL vesicles to change in appearance and nomenclature. 
Chylomicrons mature to chylomicron remnants and VLDL to intermediate-density lipoprotein (IDL) and 
further to low-density lipoprotein (LDL). These matured lipoproteins are then targets for the liver, which 
removes them from the circulation 14,15.  
The majority of new chylomicrons reach the adipose tissue for storage until times of negative energy balance 16. 
Although enterocytes and hepatocytes have a high capacity to store TGs, the main location of fat storage are 
the adipocytes within the fatty tissue. This tissue is able to fine-tune uptake and release of lipids, in order to 
adapt precisely to various metabolic states. Many different signals can affect lipolysis and export activity of 
adipocytes, as for example the stimulation by the autonomic nervous system, insulin, catecholamines, or 
cytokines 17. In order to supply extra-adipose tissue with energy, the adipocyte has to mobilize and excrete 
these TGs, which are stored in the huge LDs within the cell. This pathway is considerably simpler than the 
lipoprotein-pathway, which is the predominant export-pathway of hepato- and enterocytes. In adipocytes, TGs 
are hydrolyzed on the surface of LDs through well-controlled mechanisms, mainly involving the enzyme 
hormone-sensitive lipase. After hydrolysis of TGs, free FAs are finally transported by the fatty acid binding 
protein 4 (FABP4) out of the cell 18. Free FAs have an abysmal solubility in water at 37° C (in the nM range 
for palmitate and oleate 19), however, levels in the circulation are around 0.3 mM. This enhanced solubility is 
possible because of the plasma protein albumin. This protein is responsible for many transport functions, like 
the distribution of free FAs, of which it can bind 0.1 – 2 moles per mole protein 20. These two different 
mechanisms of lipid distribution (by lipoproteins or bound to albumin) throughout the circulation ensure proper 
supply of tissues that are in need of energy. 
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1.2 Hepatic Energy Metabolism 
Located under the rib cage and below the diaphragm in the upper-right abdominal cavity, the liver resides just 
above the small intestine. In the adult body it weighs about 1.5 – 2 kg and is made up of two main lobes (left 
and right), which are subdivided into smaller hepatic lobules. The liver is not only supplied with blood by the 
hepatic artery but also by the portal vein, making up 30% and 70% of the blood flow, respectively. About 25% 
of the cardiac output is received by the liver, mostly due to its high oxygen requirements and relative 
desaturation of oxygen in the portal venous blood 21. This organ has many essential functions, such as 
production of bile acids, protein synthesis, iron homeostasis, filtering of nutrients and antigens, and of course 
carbohydrate and lipid metabolism 22. A specific hepatic function, for example, is to supply extrahepatic tissues 
with energy. This is especially important for the brain, which heavily relies on the liver under low glucose 
conditions. For this purpose, it not only excretes VLDL, but hepatic tissue also oxidizes FAs to synthetize 
ketone bodies over the HMG-CoA pathway for further secretion. Acetoacetate and 3-hydroxybutyrate are the 
two predominant products of hepatic ketogenesis. After uptake in extrahepatic tissue, they are metabolized 
back into acetyl-CoA within the cells and are then ready to be used for adenosine triphosphate (ATP) 
production 23.  
1.2.1 Liver Mitochondria 
Like in most other tissues, energy metabolism in liver cells are closely linked to their mitochondria. Not 
without reason, they are called “the powerhouse of the cell”. Mitochondria are organelles within eukaryotic 
cells and originate from free living proteobacteria by endosymbiosis 24. They retained some of their circular 
DNA, of which they contain several copies. In humans the mitochondrial DNA encodes for 37 genes, of which 
13 are polypeptides, located in the electron transfer chain (ETC) 25. The remaining 24 genes are used for a 
functional translation of the 13 mitochondrially encoded proteins. Within the cell mitochondria are arranged 
as a network (Fig. 4a) and they orchestrate energy metabolism by substrate catabolism, as well as anabolism. 
 
 
 
Fig. 4. Mitochondrial structure and network. a) Fluorescent staining of mitochondrial network in HepG2 cells. Green color 
represents Mito Tracker green dye for mitochondria, blue color represents Hoechst 33342 dye for DNA (nucleus). The 
mitochondrial network, as well as single mitochondria are visible, with highest density around the nucleus. The picture was 
taken on an Olympus IX83 microscope, using a 100x objective. b) Schematic representation of mitochondrial morphology. 
a) b) 
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The mitochondrial network in hepatocytes is closely regulated in response to the metabolic state and other 
intracellular or environmental signals. Within the cell, the network of mitochondria undergoes constant change, 
as biogenesis and selective autophagy (mitophagy) adapt the mitochondrial content in the cell. This promotes, 
when under stress, a pool of functionally intact mitochondria 26,27. These processes are very complex and rely 
on many interactions of nuclear and mitochondrial factors. 
A way for the cell to produce ATP without mitochondria is glycolysis. Necessary enzymes are located in the 
cytosol, converting glucose to pyruvate, which yields two ATP per molecule glucose. In mitochondria, 
however, one glucose molecule, used for oxidative phosphorylation, yields 36 ATP. Therefore, it is not 
surprising that mitochondria make up a significant amount of the cell’s volume. In such a metabolically active 
cell, like the hepatocyte, the mean volume density is an impressive 27% 28. Ultimately, mitochondria are the 
main energy-supply, in form of ATP, for the cell.  
Each mitochondrion is enclosed by two membranes. The outer mitochondrial membrane smoothly envelopes 
and separates the organelles from the cytosol. Channels (porins) spanning through the outer mitochondrial 
membrane enable compounds under 5000 Da to pass freely into the inter-membrane space 29. The inner 
mitochondrial membrane, on the other hand, is a folded membrane, forming multiple invaginations, the so 
called cristae, into the mitochondrial matrix (Fig. 4b). Unlike the outer, the inner membrane is tight, which is 
especially important for retaining a proton-gradient across it. The proton gradient is built by the ETC, which 
actively pumps protons out of the mitochondria.  
Oxidative phosphorylation (oxphos) is an indispensable process for energy production in the cell. It consists 
of two linked processes, consisting of five complexes in total. Firstly, Complexes I - IV constitute the ETC, 
which produces a proton-gradient by oxidation of reduced substrates. This oxidation of substrates leads 
Complexes I, III, and IV to pump H+ out of the mitochondrial matrix, establishing a transmembrane potential. 
In a second step, this proton gradient is then used by the ATP-synthase, also called Complex V, for 
phosphorylation of ADP by inorganic phosphate. Proton influx through the membrane spanning part of the 
enzyme causes rotation of the catalytic part. Ultimately, this rotation-energy is used for the phosphorylation of 
ADP (Fig. 5).  
Accordingly, the maintenance of the mitochondrial membrane potential (ΔΨ) is of utmost importance for a 
functional energy production by mitochondria. Several compounds are known to interfere with this potential 
by channeling protons through the membrane. These so-called uncouplers are usually lipophilic weak acids, 
which get protonated in the inter-membrane space, where the pH is low, then diffusing across the membrane. 
In the matrix, where the pH is higher, they lose the proton and thus circumvent the translocation of protons by 
Complex V, ultimately stimulating respiration by Complex I-IV, however, without the synthesis of ATP. The 
first known uncoupler, 2,4-dinitrophenol, was observed in 1885 by French scientists, showing acceleration of 
metabolism and increase in body temperature in dogs 30. It then was investigated thoroughly during the First 
World War, because of increased numbers of dying workers in explosive factories, manufacturing shells and 
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hand grenades containing this substance. Poisoned workers showed very high body temperatures (up to 45° C), 
gastro-intestinal disturbances, anorexia, nausea, loss of weight, and immediate rigor mortis after death, which 
led to preventive measures, like the placing of asbestos curtains, washable gloves, daily baths and change of 
clothes, or other sanitary- and also eating-regulations. Furthermore, 2,4-dinitrophenol also caused many 
casualties in the 1930s, when it was observed, that women were taking the compound to induce weight loss 31. 
 
 
 
 
 
Naturally, for their proton translocation, Complexes I-V are therefore integrated in the inner mitochondrial 
membrane. Complex II, the succinate-coenzyme Q reductase, links the oxphos pathway with the Krebs-cycle, 
which is also called tricarboxylic acid cycle (TCA). Located in the mitochondrial matrix, the TCA connects 
the protein, carbohydrate and lipid metabolism. Eight enzymes carry out a series of reactions that completely 
oxidize acetate (as acetyl-CoA) into two molecules of carbon dioxide and water. One cycle yields three NADH 
and one FADH2, further fueling the ETC. 
Lastly, long-chain FAs catabolism yields a notable amount of acetyl-CoA for further metabolism and energy 
production. Relevant pathways and connections concerning lipids are discussed in detail in the next section.  
Fig. 5. Oxidative phosphorylation pathway (oxphos). The process of oxidative phosphorylation is the main pathway within the 
cell to produce ATP. It consist of two distinct processes embedded into the inner mitochondrial membrane, the ETC and the 
ATP synthase (Complex V). In the ETC reduced substrates, such as NADH, FADH2, and succinate are oxidized by the NADH-
ubiquinone oxidoreductase (Complex I), ETFDH, and succinate-CoenzymeQ reductase (Complex II), respectively. These 
proteins transfer electrons from their substrates onto Q-10, which is substrate for the CoenzymeQ-cytochrome c 
oxidoreductase (Complex III). Q-10 is a highly lipophilic substance, able to diffuse within the inner mitochondrial membrane. 
Complex III transfers the electrons from Q-10 onto cytochrome c, a water-soluble electron carrier, located at the surface of the 
inner mitochondrial membrane, in the inter-membrane space. In the final step of the ETC, cytochrome c oxidase (Complex 
IV) uses the electrons from reduced Q-10 to reduce molecular oxygen to water. In the process of transferring electrons Complex 
I, III, and IV actively move protons (H+) from the mitochondrial matrix to the inter-membrane space, forming the 
mitochondrial membrane potential (ΔΨ). This potential is ultimately used by the ATP Synthase (Complex V) to form ATP 
from ADP and an inorganic phosphate. The reverse proton pumping action of this enzyme leads to a rotation of the subunit 
facing into the mitochondrial matrix. This rotational energy causes conformational changes in the catalytic sites of the enzyme, 
allowing it to bind ADP and a phosphate, fusing the two, and finally releasing ATP. The shapes of the enzymes in this scheme 
are based on crystal-structures, however, in reality the enzymes of oxphos are arranged together as supercomplexes. 
Abbreviations: ETC: electron transfer chain, ETFDH: electron-transferring-flavoprotein dehydrogenase, Q-10: 
coenzymeQ10.  
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1.2.2 Hepatic Lipid Metabolism in Detail 
Besides enterocytes and adipose tissue, the liver is the main organ for metabolism of lipids. Within the liver, 
which harbors many different cell types, the hepatocytes are responsible for the bulk of lipid metabolism in 
this organ. On a cellular level, the organelles, most involved in the metabolism of lipids, are the mitochondria, 
wherein the most important lipid metabolism pathways take place. High levels of unesterified FAs within the 
cell can pose a serious problem and cause lipotoxicity. In order to avoid overload as well as deprivation, lipid 
metabolism has to be closely coordinated by the cell. There are five major ways with which the hepatocyte can 
adapt levels of intracellular TG, free FAs, and intermediates: Uptake, degradation, synthesis, storage, and 
excretion. 
1.2.2.1 Uptake and Activation 
FAs circulate in plasma mostly bound to serum albumin. The cellular uptake mechanism is quite complex 
involving dissociation of FAs from serum albumin and transport across the cell membrane. Although not the 
only uptake mechanism for lipoproteins, the low-density lipoprotein receptor (LDLR) expressed on 
hepatocytes recognizes and binds ApoE for subsequent uptake by the cell. When ApoE is present on former 
VLDL or chylomicron particles, one speaks of remnant-lipoproteins, for which the liver has a high affinity for 
clearance from the circulation 15.  
Free short- and medium-chain FAs are able to pass the hepatocyte membrane by passive diffusion, while FAs 
with longer chain length (>C12) rely on active transport 32,33. FATPs, responsible for this transport, are integral 
membrane proteins with six isoforms of high homology (FATP1 – FATP6). In the liver, FATP5 is the FATP 
with the highest expression and importance. FATP5, like its other isoforms, exhibits acyl-CoA synthetase 
activity after translocation of the FAs across the plasma membrane. This so called activation, the esterification 
of a FA to coenzyme A (CoA), is a step imperative for functional metabolism within the cell. About 4% of 
known enzymes utilize the acyl carrier CoA as an obligate cofactor 34-36. The activation process of FAs can not 
only be executed by the FATPs, but is predominantly carried out by acyl-CoA synthetases (ACSLs). After the 
initial report of ACSL1 in 1953, 26 different isoforms (encoded by five genes) were subsequently identified 
in humans and mice. These ACSLs differ in tissue expression, cellular localization, substrate specificity, as 
well as on the metabolic destination (e.g. breakdown vs. synthesis) of their product. The situation, therefore, 
is very complex and still open for elucidation. What is known, however, is that in the liver the most expressed 
isoforms, responsible for the activation of long-chain FAs are ACSL1 (50% of hepatic activity), ACSL4, and 
ACSL5. ACSL1 and ACSL5 are reported to channel their activated FAs mostly towards TG synthesis, while 
the direction of channeling for other ACSLs are mostly speculative 34,37-39. 
1.2.2.2 Degradation 
The mitochondrial β-oxidation pathway is the central pathway to break down FAs within the cell, constituting 
up to 95% of overall FA-oxidation activity 40 in the liver. As stated above, mitochondrial β-oxidation is located 
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within the mitochondrial matrix. Activated FAs (acyl-CoAs), however, are too polar to cross the inner 
mitochondrial membrane. Therefore they have to be actively transported into the mitochondrial matrix. This 
import is carried out by three consecutive proteins: carnitine palmitoyltransferase 1 (CPT1), carnitine-
acylcarnitine transferase (CACT), and CPT2 (carnitine shuttle).  
CPT1 catalyzes the formation of long-chain acylcarnitines from acyl-CoAs and free carnitine. Localized at the 
outer mitochondrial membrane, it is the committing and rate-limiting step for mitochondrial β-oxidation. As 
acylcarnitine-entity, they are targets for the CACT, which imports one acylcarnitine and exports one free 
carnitine. Inside the mitochondrial matrix CPT2 carries out the reverse reaction of CPT1 – the transfer of the 
FA from carnitine to a free CoA. As FA-CoA, inside the mitochondrion, it can then undergo β-oxidation 41,42.  
Fully saturated straight chain FAs undergo β-oxidation until their full degradation to a final acetyl-CoA or 
propionyl-CoA, yielding acetyl-CoA, FADH2, and NADH, for every two-carbon-shortening of the FA 42. 
Omitting chain length specificities and unsaturated/branched FAs, β-oxidation proceeds in four reiterating 
steps, as shown in Fig. 6. Of the aforementioned products of the β-oxidation cycle, NADH and FADH2 are 
oxidized as cofactors in the ETC. NADH is used by Complex I and FADH2 is transported over the electron-
transferring-flavoprotein (ETF) to the electron-transferring-flavoprotein dehydrogenase (ETFDH). ETFDH 
feeds the electrons from FADH2 to the coenzyme Q pool, to ultimately contribute to the Complex III activity 
41,43 (Fig. 7). Although over 90% of FA oxidation is carried out by β-oxidation in the mitochondrial matrix, 
there is an alternative pathway by which the cell can break down FAs. The so-called ω-oxidation starts with 
the hydroxylation on the ω-carbon (carbon at the opposite site of the preexisting carboxyl group) by members 
of the cytochrome P450 (CYP) 4A and 4F subfamilies, which are associated with the membrane of the ER. 
After further oxidation to dicarboxylic acids by an alcohol- and aldehyde-dehydrogenase, they are translocated 
to peroxisomes, where they undergo peroxisomal β-oxidation 40.  
Fig. 6. Simplified four-step reaction cycle of mitochondrial β-oxidation of saturated straight-chain FAs.  
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Peroxisomal β-oxidation, however, can only metabolize very long- and long-chain FAs and not medium- nor 
short-chain FAs or respective dicarboxylic acids. For complete breakdown, they have to be transported into 
mitochondria 44. Furthermore, peroxisomal β-oxidation enzymes differ slightly from the mitochondrial forms. 
Breakdown in peroxisomes only produces one NADH and is directly coupled to O2 and not to the ETC 45. The 
product of FA oxidation, acetyl-CoA, has many fates in the cell. For instance, it can be used right in the 
mitochondria for feeding into the citric acid cycle, for protein acetylation, for ketone body synthesis, but also 
as building block for many other pathways of the cell. Namely, it is the precursor for FA synthesis 46-48. 
 
 
 
 
Fig. 7. β-oxidation pathway in humans. Overview of proteins and reactions involved in the mitochondrial breakdown of short-, 
medium-, and long-chain FAs. After activation of the FA to FA-CoA, by an ACSL and the use of one ATP, long-chain acyl-
CoAs are translocated into the mitochondrial matrix by the carnitine shuttle. Short- and medium-chain FAs can also cross the 
inner mitochondrial membrane by diffusion and get activated by ACSLs, present in the matrix. The carnitine shuttle consists 
of three proteins: CPT1, CACT and CPT2. CPT1 catalyzes the formation of long-chain acylcarnitines from acyl-CoAs and free 
carnitine. Localized at the outer mitochondrial membrane, it is the committing and rate-limiting step for mitochondrial 
β-oxidation. As acylcarnitines, they are targets for the CACT, which imports one acylcarnitine and exports one free carnitine. 
Inside the mitochondrial matrix CPT2 carries out the reverse reaction of CPT1 – transfer of the FA from carnitine to a CoA. 
Inside the mitochondrion as acyl-CoA, it then can undergo β-oxidation. The first reaction involves a FAD-linked 
dehydrogenation of acyl-CoA to yield trans-2-enoyl-CoA, which is catalysed by chain-length specific acyl-CoA dehydrogenases. 
For the next step, one of the two ECHs hydrates the carbon double-bond, which is followed by a NAD+-linked dehydrogenation, 
carried out by one of the two HADHs, to yield 3-keto-acyl-CoA. The final step is carried out by the LC Thio for longer forms, 
and for shorter forms by SC Thio. They cleave 3-keto-acyl-CoAs by the thiol group and transfer the remaining acyl-chain to a 
free CoA, finally producing an acetyl-CoA and a two-carbon shortened acyl-CoA, which can undergo the cycle again. The LC 
ECH, LC HADH and LC Thio are aggregated to one protein complex, called the TFP. Abbreviations: ACSL: acyl-CoA 
synthase, ATP: adenosine triphosphate, CACT: carnitine-acylcarnitine translocase, carn.: carnitine, CPT: carnitine-palmitoyl 
transferase, ECH: enoyl-CoA hydratase, ETC: electron transfer chain, ETF: electron transfer flavoprotein, FA: fatty acid, 
HADH: 3-hydroxyacyl-CoA dehydrogenase, LC: long-chain, LCAD: long-chain acyl-CoA dehydrogenase, MC: medium-chain, 
MCAD: medium-chain acyl-CoA dehydrogenase, SC: short-chain, SCAD: short-chain acyl-CoA dehydrogenase, TCA: 
tricarboxylic acid cycle, TFP: trifunctional protein, Thio: 3-keto-thiolase. 
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1.2.2.3 Fatty Acid and Triglyceride Synthesis 
De novo lipogenesis is the combined metabolic pathway, consisting of glycolysis and the biosynthesis of new 
FAs to produce TGs. FA-synthesis is started by the irreversible carboxylation of acetyl-CoA to malonyl-CoA 
by acetyl-CoA carboxylase (ACC). In a next step, the multifunctional enzymatic complex, the fatty acid 
synthetase (FAS), made up of six enzymes functionally fused together, catalyzes the formation of palmitate by 
the elongation of one acetyl-CoA with seven malonyl-CoAs, with the use of one NADPH per elongation step 
49,50. The liver, like other lipogenic tissues, is greatly capable of synthesizing TGs from FAs and glycerol, a 
product from glycolysis. After formation of glycerol-3-phosophate by glycerol kinase, the first, committing 
and rate-limiting step of TG-synthesis is catalyzed by glycerol-3-phosphate acyltransferase (GPAT), which 
transfers a free FA to the phosphorylated glycerol. In the liver, two isoforms essentially share the bulk of this 
first acylation step, the microsomal GPAT and the mitochondrial GPAT (GPAM). Lysophosphatidic acid 
(single-acyl glycerol-phosphate) is then acylated again to form diacyl glycerol (DAG), which is the branch 
point between phospholipid and TG synthesis. In order to finally form a TG, DAG is acylated one more time 
by diacylglycerol acyltransferase-1 (DGAT) 46. 
1.2.2.4 Trafficking and Storage 
In order to avoid toxic levels of intracellular free FAs, the cell possesses several strategies to react. One way 
is the notably high content of fatty acid binding protein (FABP) in hepatocytes. In the liver, approximately 
10% of cellular protein consists of FABP1, which binds and therefore “detoxifies” free FAs, FA-CoAs, FA-
carnitines, as well as other intermediates of lipid acid metabolism. Furthermore, FABP is of great importance 
for the intracellular transport of its ligands, as it is believed, that through protein-protein interactions of FABP 
and other proteins, substrates are moved in a targeted way within the cell. One example is FABP-dependent 
translocation to the nucleus, in order to deliver peroxisome proliferator-activated receptor (PPAR)α or PPARγ 
agonists, which often have a high binding-rate to FABP 51-53. 
Synthesis of neutral TGs is also a way for the cell to limit levels of free FAs. Besides binding to proteins like 
FABP, TGs are normally stored in LDs within the cell. Those LDs are stabilized vesicles, filled with mainly 
TGs, and enveloped by a mono-layer of phospholipids, which are complemented with numerous proteins, 
important for the handling of this energy-rich storage. LD-proteins are important for the stabilization, as well 
as for intracellular displacement of LDs for specific functions, as for example for excretion purposes 54.  
Adipose differentiation-related protein (ADRP), also known as Perilipin 2, is an important protein on the 
surface of LDs. One function of it, for example, is to regulate membrane dynamics and lipolysis on the surface 
of LDs. As an integral LD-protein it is positively correlated with cellular lipid droplet content, and therefore 
also TG content 55,56. A similar group of LD-associated proteins is the CIDE (cell death-inducing DNA 
fragmentation factor-α-like effector) family. They are localized on the LD surface and are particularly enriched 
at LD-LD contact sites, controlling LD fusion and size. Like ADRP, Cidea and Cidec are positively correlated 
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with the LD content of the cells, however their specific roles in promotion of TG accumulation are still 
controversial 57,58.  
1.2.2.5 Export 
Finally, the hepatocyte can also actively excrete the TGs within the cell to the system. For anabolic and energy 
requirements VLDL is synthetized in the liver and excreted for the supply of extrahepatic tissue, very similar 
to the situation in enterocytes, described above. VLDL consists of a core of TGs and cholesteryl esters, which 
is surrounded by a monolayer of phospholipids and cholesterol with specific apolipoproteins embedded. The 
full length ApoB, ApoB100, is a structural protein, essential for the formation and stability of VLDL vesicles, 
as well recognition thereof by extrahepatic tissue 59,60.  
The mechanism of the whole VLDL synthesis is quite complex and not yet fully understood, however, very 
similar to the synthesis and excretion of chylomicrons (Fig. 3). Briefly, it starts at the ER membrane, the 
location of ApoB-synthesis. After translation to the luminal side of the ER, various lipids and multiple copies 
of other apolipoproteins are a recruited to the ApoB. The microsomal triglyceride transfer protein (MTTP), an 
enzyme crucial for the pathway, then transfers the bulk of TGs from the ER-TG pool to the newly forming 
VLDL particle 59,61,62. If the ApoB is not properly lapidated, it is degraded again, before exiting the ER 60. After 
translocation to the Golgi and subsequent modification, it is excreted to the circulation via exocytosis 63.  
Through a mostly unknown mechanism, hepatocytes are also able to excrete FAs through the cell membrane, 
in the form of acyl-carnitines 64. Since acyl-CoAs are too polar for crossing biological membranes by diffusion, 
and there is no efficient transport system in place, they cannot leave hepatocytes in this form. Acyl-CoAs, 
however, can be converted to the corresponding acyl-carnitines. As acyl-carnitines they can not only leave the 
mitochondria over the carnitine shuttle, but also the cell, thus reaching the bloodstream and also urine. 
Consequently, in addition to its role in the mitochondrial β-oxidation pathway, carnitine is important for the 
protection of the cellular CoA pool. It provides the cell with a mechanism to maintain CoA availability for 
CoA-dependent reactions under conditions of acyl-CoA accumulation 65. 
1.2.3 Regulation of Hepatic Lipid Metabolism 
Hepatic lipid metabolism has to be capable to respond to various situations, such as postprandial spikes in FA 
availability or the need for de novo lipogenesis. Also the distribution of energy-rich substrates, like ketone 
bodies for extrahepatic tissue during fasting or prolonged exercise, needs responsive mechanisms. Therefore, 
many regulatory pathways are in place, able to alter metabolic rates and protein expressions of enzymes 
involved.  
Above all, adaption of mitochondrial mass is a major way for the cell to adapt to metabolism-related changes 26. 
Mitochondrial biogenesis and degradation, still under much needed investigation, are mainly regulated by 
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nuclear factors. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) is described 
as master regulator in this pathway. It is a transcriptional coactivator, which induces the activity of the 
transcription factors nuclear respiratory factor 1 and 2 (NRF1 and 2). They, themselves, regulate the 
transcription of the mitochondrial transcription factor A (TFAM), which is responsible for the replication of 
mitochondrial DNA, and the expression of many other genes, linked to mitochondrial biogenesis and metabolic 
activity 26,66,67.   
FAs are ligands of PPARα, which is the most important control element for FAs oxidation. It has been shown, 
that strong agonists for this adopted orphan receptor are mostly dietary polyunsaturated FAs and newly 
synthesized FAs 68. When activated, PPARα upregulates almost all of the enzymes connected to FA 
degradation. Examples are CPT1, FABP, CYP4A11, or the medium-chain acyl-CoA dehydrogenase (MCAD), 
as well as genes for carnitine biosynthesis 69,70. Such nuclear receptors consist besides of a ligand binding site 
also of a central DNA-binding domain that binds to specific sequences within a gene promotor. Binding of 
ligands will lead to recruitment of coactivators, resulting in chromatin remodeling with subsequent DNA 
transcription 68. Besides from its ligands, PPARα is also regulated by various other stimuli, which are 
associated, for example, with dietary status (Fig. 8). 
Fig. 8. PPARα as molecular switch directing energy 
metabolism. Shown are influences of fed states (red 
arrows) and fasting states (green arrows) on the 
activity of PPARα and its downstream control. 
Postprandial glucose leads to production and 
secretion of insulin by the pancreas, which induces 
hepatic glucose uptake and glycolysis, yielding 
AcCoA, which induces FA synthesis. Insulin leads to 
phosphorylation of PPARα via PKC and thereby 
enhances its transcriptional activity. Insulin-
activated mTORC1 blocks PPARα activity. FAs and 
FA-derivatives are direct activators of PPARα. 
During fasting, hormones such as adrenaline and 
glucocorticoids are synthesized together with 
glucagon. Glucagon sustains hepatic gluconeogenesis 
and increases cAMP levels, triggering PKA-
dependent PPARα phosphorylation and activity. 
Fasting leads to decreased mTOR1C activation, thus 
stimulating PPARα-dependent FA oxidation and 
ketogenesis. The fasting-induced release of FAs from 
adipose tissue raises plasma levels of free FAs that are 
subsequently taken up and stored in the liver as TGs. 
LIP-dependent hydrolysis of hepatic TGs provides 
FA-ligands for PPARα activation, which leads to 
increased β-oxidation rates directly and via FGF21-
activation, to provide substrates for ketone body 
synthesis and gluconeogenesis, thus maintaining 
energy supply for extrahepatic tissues. The scheme is 
adapted from Pawlak et al. 1. Abbreviations: AcCoA: 
acetyl-Coenzyme, AMP: adenosine monophosphate, 
AMPK: AMP-activated protein kinase, DGAT: 
diglyceride acyltransferase, FA: fatty acid, FFA: free 
fatty acid, FGF21: fibroblast growth factor 21, LIP: 
lipase, mTORC1: mammalian target of rapamycin 
complex 1, P: phosphorylation, PKA: protein kinase 
A, PKC: protein kinase C, PPARα: Peroxisome 
proliferator-activated receptor α, TG: triglyceride.  
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Effects on transcriptional regulations are usually long-term adaptions, however, acute activity-regulations are 
possible by substrate-feedback. Most importantly, CPT1, the rate limiting step in the catabolism of FAs, is 
negatively regulated by levels of malonyl-CoA, the substrate for FA-synthesis 41. Therefore, under conditions 
with high availability of energy in the form of acetyl-CoA, ACC is increasingly building malonyl-CoA, which 
inhibits CPT1 by binding to a high-affinity binding site 71. Accordingly, the cell downregulates the usage of 
FAs for ATP production under this condition.  
Acetyl-CoA levels can also acutely affect the metabolism over the AMP-activated protein kinase (AMPK). If 
energy levels are low and adenosine monophosphate (AMP) levels are high, AMPK phosphorylates ACC, 
which decreases its activity and therefore decreasing malonyl-CoA levels. This leads to a shift in metabolism 
away from lipogenesis and towards breakdown 41,42,48. Furthermore, acetyl-CoA availability also affects the 
acetylation-status of mitochondrial proteins, and therefore their activity 72. One example thereof is the 
activation of PGC1α by deacetylation, carried out by sirtuin-1 73.  
The regulation of TG synthesis is equally complex and alters greatly in different tissues. The most important 
players are the transcription factors sterol regulatory element-binding protein 1c (SERBP-1c) and PPARγ, as 
well as hormonal and nutritional regulators 46. SREBP-1c is mainly activated by insulin and repressed by high 
levels of polyunsaturated FAs 74. When activated, for example by the insulin pathway, it translocates from the 
ER to the nucleus and upregulates the transcription of lipogenic proteins such as ACC, GPAM, and FAS 75.   
PPARγ, like other PPARs is a nuclear receptor belonging to the steroid receptor superfamily, which are 
activated by FAs 76. When an agonist binds, corepressors around the PPAR disassociate and it can then form 
a complex with the retinoid X receptor. Together they recruit different coactivators, like PGC1α, and induce 
transcription of specific genes. PPARγ controlled genes are in the hundreds and include Cidec, LPL, 
cytochrome C, CD36, FATP1, ADRP, FAS, Glut4 (glucose transporter type 4), and many more 77. Activation 
therefore mostly leads to increased glucose metabolism and TG storage.  
Estrogen receptors (ESRs) are not only important for female traits and development, but also for general energy 
metabolism in vertebrates. Upon activation, ESRs can initiate biological events within days and hours, but 
over the cell membrane, even in seconds 78. There are two types of ESRs: nuclear ESRs and membrane ESRs. 
However, they are not only present in the cell membrane and the nucleus, but also reported in mitochondria 
79,80. Most of the known transcriptional effects of estrogen, however, are nuclear-initiated. When activated, 
ESRs translocate from the plasma to the nucleus, where they recruit transcriptional machinery and other 
cofactors to specific DNA sequences 81. It is known that estrogen benefits insulin sensitivity and lipid 
metabolism, the mechanism behind it, however, is still poorly understood 82,83. 
Another emerging pathway involved in lipid metabolism is the endocannabinoid system. It is clear that the 
endogenous cannabinoids arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol have an 
important role in food intake and body weight as they have effects on appetite and response to diet 84,85. There 
are two types of cannabinoid receptors present in the body, with quite different effects. Endocannabinoids, 
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synthesized in the liver from essential FAs like linoleic acid 84, exert their effects over the following two 
receptors: cannabinoid-receptor 1 and 2 (CB1 & CB2) 86,87. CB2 activation is mostly expressed on cells of the 
immune system and is attributed to positive effects regarding inflammation and lipid homeostasis 88. CB1 
activation, on the other hand, is closely linked to a greater steatogenic risk potential in humans 89. Furthermore, 
animal studies in mice and rats clearly showed the necessity of CB1 expression for developing hepatic steatosis 
under high fat or high alcohol diet 90,91. CB1 activation not only results in an upregulation of the lipogenic 
transcription factor SREBP1c and its target enzymes, but also appears to regulate hepatic FA oxidation by 
decreasing the activity of CPT190,92. Finally, cannabinoids not only exert their effects through CB receptors on 
the cell membrane, but also through receptor-independent mechanisms 93,94, as well as through CB receptors 
located in the mitochondrial membrane 95. The understanding of mechanistics behind the CB receptor mediated 
effects, unfortunately, is still incomplete, especially in regard to the role of cannabinoids on mitochondria 96-
99. 
Apparent from the examples of regulations of hepatic lipid metabolism above, multiple regulatory pathways 
are connected in different ways for the fine-tuning of hepatic energy homeostasis. Similarly, these regulatory 
mechanisms generally affect other metabolic pathways as well, such as glycolysis or oxphos, which is 
comprehensible, since almost all ATP-producing pathways are in some way interlinked. These pathways are 
not only linked over identical upstream master-regulators, such as PPARs, but also over substrate interchange 
(Fig. 9) or feedback mechanisms.  
 
Fig. 9. Overview of interlinked metabolic pathways. Shown is a mitochondrion, with respective intra-mitochondrial metabolic 
pathways and the glycolysis, which is located in the cytosol. Abbreviations: ADP: adenosine diphosphate, ATP: adenosine 
triphosphate, C.II: Complex II, C.V: ATP synthase, ETC: electron transfer chain, FA-CoA: fatty acid-Coenzyme A, FADH: 
flavin adenine dinucleotide, NADH: nicotinamide adenine dinucleotide, PDC: pyruvate dehydrogenase complex, TCA: 
tricarboxylic acid cycle, β-ox.: β-oxidation. 
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1.3 Liver Injury and Metabolic Imbalance 
The liver is a site, which receives multiple xenobiotics and waste products to detoxify. Under normal 
circumstances, it is perfectly able to carry out this task. However, in some cases, it cannot cope with the demand 
and is damaged in the process, if the burden goes on. Typical challenges for the liver, which lead to injury, are 
cholestasis 100, chronic alcoholism, ischemia, autoimmune or viral hepatitis, as well as toxic liver injury 101. 
For clinicians the first indication of liver injury is often the pattern of liver enzyme alterations. The eminent 
thereof are alanine amino transferase (ALT) and aspartate amino transferase (AST). Both are cytoplasmic 
enzymes found in hepatocytes. When found elevated in the blood of patients, it therefore suggests damaged 
hepatocytes 102. Other relevant biomarkers for liver injury are elevated serum bilirubin, gamma-glutamyl 
transferase, alkaline phosphatase, or low serum albumin.  
In view of xenobiotics, the liver is especially at risk of damage. Nowadays, most drugs are lipophilic and 
undergo extensive hepatic metabolism to render them more hydrophilic, in order to excrete them via the urine. 
The lipophilicity of drugs and the fact that those drugs reach the liver right after gastrointestinal uptake, can 
lead to a much higher drug and metabolite concentration in the liver, compared to other tissues. For instance, 
these membrane partitioning and accumulation effects are well known for tamoxifen 103,104 or also for tyrosine 
kinase inhibitors 105,106. 
Drug-induced liver injury (DILI) can be classified into two types regarding their predictability. Intrinsic 
toxicity causes liver injury in a dose-dependent fashion and is predictable 107. The most used example thereof 
is the toxicity of acetaminophen (paracetamol), of which the mechanism of toxicity is known very well, as 
well as the dose- and time dependency. Idiosyncratic toxicity, on the other hand, is unexpected and not strictly 
dose-dependent. Furthermore, it only affects a small proportion of patients and also cannot be predicted by its 
pharmacological action 108. Due to the low incidence and unpredictability, it is evident that patients developing 
idiosyncratic DILI possess or acquired underlying factors, making them susceptible for these currently 
unknown mechanisms of toxicity. 
In this thesis, the focus lies on the elucidation of molecular mechanisms of drugs causing idiosyncratic 
hepatotoxicity. More precisely, the drugs chosen for investigation have all a common type of outcome: hepatic 
steatosis. 
 
 
17 
 
1.3.2 Hepatic Steatosis 
Steatosis of the liver is defined by an excess accumulation of intracellular TGs within the hepatocytes. One 
differs between two types of steatosis, the macrovesicular and microvesicular form.  
The histological representation of macrovesicular steatosis is described as fatty hepatocytes, which contain a 
large droplet of fat with peripheral displacement of the nucleus. Microvesicular steatosis, on the other hand, is 
characterized by an abnormal accumulation of multiple small LDs without nucleus displacement 109 (Fig. 10). 
Diagnosis relies on liver function tests and imaging with the exclusion of other liver diseases. The gold 
standard, however, still is to perform a liver biopsy with subsequent histological evaluation, where at least five 
percent of cells have to show lipid accumulation 110. 
Hepatic steatosis, which is not a result of excessive alcohol intake, is also called nonalcoholic fatty liver disease 
(NAFLD). It ranges from simple steatosis to nonalcoholic steatohepatitis. NAFLD is a serious health problem 
worldwide, reported to affect 15 – 30 % of the population in developed countries 111. Macrovesicular steatosis, 
often associated with excess alcohol exposure or treatment with glucocorticoids, usually, is a form of injury, 
which is reversible. The microvesicular form, however, is a more severe injury of the liver, typically associated 
with mitochondrial dysfunction and can aggravate significantly 112. If not managed in a timely manner, 
steatosis can worsen to steatohepatitis, cirrhosis, and also to liver failure. Ultimately, severe liver injury with 
microvesicular steatosis often ends fatally in the absence of liver transplantation 113.  
As NAFLD is directly associated with obesity, the management of this disease typically lies, in a first approach, 
on changes in lifestyle and diet. The treatment for more progressed forms can include supplementation of 
antioxidants like vitamin E, drugs to increase insulin sensitivity, fibrates against dyslipidemias, and statins. 
Liver transplantation, as a last resort, is increasingly used as well 114,115. 
Inordinate accumulation is damaging to the liver, because high levels of TGs, free FAs, or intermediates of 
lipid metabolism are extremely problematic for a cell. Especially excessive free FA concentrations pose a 
serious problem. Not only can the detergent-like effect of FAs damage membranes, but also peroxidased FAs 
Fig. 10. Tissue- and histologic representation of hepatic steatosis and fibrosis. Shown 
are livers from rats. On the left excised livers are shown. On the right hematoxylin and 
HE stained sections are shown with different magnifications. Abbreviations: AFL: 
alcoholic fatty liver, NAFL: non-alcoholic fatty liver, HE: hematoxylin and eosin. The 
figure is adapted from Liu et al. 2. 
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are a grave consequence of FA overload. FA peroxidation occurs mainly on unsaturated FAs at the location of 
double bonds 116. It is initiated, when a hydrogen atom is abstracted form a CH2 group of a FA. Reactive oxygen 
species (ROS), which are able to abstract a hydrogen, are for example superoxide- and hydroxyl radicals, 
produced in the mitochondria. Superoxide anions (O2∙-) can arise from the activities of Complexes I and III of 
the ETC. The greatest portion of ROS is produced by Complex I of the respiratory chain. ROS formation 
occurs, when unpaired electrons escape the respiration chain and are accepted by O2 117. Superoxide 
dismutase 2, localized in the mitochondria, scavenges superoxide radicals by catalyzing two O2·¯ to a hydrogen 
peroxide. Hydrogen peroxide is then catalyzed into water and O2 by the enzyme catalase. Alternatively, due to 
iron ligands present in the mitochondrial matrix, which allow for redox-cycling, hydroxyl radicals can be 
formed through the Fenton reaction 118. Not only FAs can get peroxidised, but also cholesterols and 
phospholipids. Lipid peroxidation gives complex products, such as aldehydes, polymeric materials, and lipid 
radicals, which all are cytotoxic 116. Under normal circumstances, the cell is able to detoxify radicals promptly 
through binding to the antioxidant glutathione (GSH), however, if oxidative stress surpasses the antioxidative 
capacity, membranes, proteins, and DNA can get damaged through these highly reactive molecules. 
In the case of palmitate, the most abundant endogenous FA119, an excess of C16-ceramide formation can occur 
in the cells 35,51. Ceramides belong to the structurally diverse class of sphingolipids, which make up a 
significant amount of membrane lipids. When there is a disproportionate ceramide formation it leads to 
membrane permeability, pore formation, and altered cell signaling of membrane proteins. These changes 
ultimately will lead to programmed cell death (apoptosis) 120. 
The exact mechanism behind the accumulation of excess lipids in the liver is complex and multifactorial. 
Different theories have been formulated on the topic, assenting on the “two-hit hypothesis” 121. Accordingly, 
pathological lipid accumulation in the liver occurs after a second hit, meaning a further insult to hepatic 
metabolism, after it has already been sensitized from the first hit. The case report of a patient, who died after 
treatment with valproate is a good example thereof 122. This patient was treated for epilepsy with valproate, 
which is known to interfere with FA metabolism123, upon which he died. This was the second hit. After 
postmortem investigation in cultured fibroblasts, it was found that the patient had an underlying deficiency in 
an enzyme, which is important for the metabolism of medium-chain FAs, which represents the first hit in this 
case. First hits, or in other words underlying susceptibilities, can also be insulin resistance, sedentary lifestyle, 
high fat diets, or many forms of mitochondrial dysfunction 121.  
Lastly, a “hit” to increase FA content can be caused by disruption of one or more of the pathways, which are 
involved in the regulation of FA and TG levels in the hepatocyte. Namely, the uptake and activation of free 
FAs can be increased, de novo lipogenesis can be elevated, FA degradation in mitochondria and peroxisomes 
can be reduced, or finally TG export by VLDL secretion can be decreased (Fig. 11). 
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1.4 Investigation 
1.4.1 Why Study Hepatic Lipid Metabolism? 
Globally, NAFLD is the most common cause of liver disease, affecting up to 58% of overweight individuals 
111. The problem of obesity in the general population has tremendously gained importance over the last century. 
In most western countries chronic diseases, related to diet, represent the largest cause of morbidity and 
mortality. An obvious component of this multifactorial problem is the steadily increasing consumption of 
refined vegetable oils, with high contents of fully saturated- and trans-fats 6 and a sedentary lifestyle. A further 
problem is that NAFLD can obviously be a risk factor for developing adverse reactions to drugs, interfering 
with hepatic lipid metabolism, leading to idiosyncratic DILI.  
Furthermore, DILI has been the major cause of drugs failing approval, black box warnings, as well as 
withdrawal from the market over the last 50 years 124,125. DILI usually appears in a small population of patients, 
often missed in clinical phases 1 and 2. The pharmaceutical industry, therefore, makes great efforts to find and 
establish safe biomarkers for the preclinical assessment of possible toxicity 124. 
Fig. 11. Graphical representation of pathways, with which the cell can regulate lipid content. Abbreviations: BC: bile 
canaliculus, carn: carnitine, CoA: coenzyme A, ER: endoplasmic reticulum, FA: fatty acid, LD: lipid droplet, Lip.Prot: 
lipoprotein, TG: triglyceride, VLDL: very-low density lipoprotein.  
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Many mechanisms are known that can cause hepatic steatosis. In the case of drug-induced hepatic steatosis, 
however, a lot of questions still remain unanswered. Consequently, in order to save both lives and money, 
elucidations of mechanisms leading to adverse reactions on the liver are needed for better disease prevention 
and handling, ultimately increasing quality of life in affected individuals. 
1.4.2 Models for Investigation  
Whether it is the use of animal models, tissue cultures, cell cultures, microsomes, homogenate fractions, single 
enzyme preparations, or in silico modeling, every model of investigation has advantages and disadvantages. It 
is up to a systematic decision process for choosing the model best applied for respective scientific 
investigations. Today, besides clinical studies, animal 
models are viewed as closest to the situation in human, 
in most cases. The high costs, labor intensity, 
availability of animal facilities, and ethical 
considerations, however, lead most scientific work to 
remain in vitro. Testing in cell cultures also has its 
advantages over studies in vivo. Testing in vitro is highly reproducible, reduces the costs of investigation 
tremendously and allows for a very high number of experiments. Moreover, it allows for the use of human 
material, as species differences could render findings in animals hard to interpret.  
There has been a long way from first observations in nature, over early animal vivisections and experiments 
on criminals, to the situation today, where we scientists are blessed with uncountable models of investigations 
to choose from. Still, in the second half of the nineteenth century with the beginning of scientifically 
meaningful animal research126, experiments were mostly performed for physiological knowledge. Scientific 
studies on toxicity began in 1920, when J.W. Trevan proposed the use of the 50% lethal dose (LD50), followed 
by methods for testing eye and skin irritation in rabbits 127. In the same time, work on first continuous primary 
cell cultures started. Based on early works, like the experiments 1882 by Sydney Ringer128, who developed the 
Ringer’s solution for keeping excised tissues functional for a short period of time, or 1885 work by Wilhelm 
Roux129, who managed the first sustained maintenance of tissues ex vivo. Eventually in the 1943s the first 
permanent cell line emerged from subcutaneous mouse tissue130. February 1 1951, was the day when Henrietta 
Lacks visited the Johns Hopkins Gynecology Clinic in Baltimore, Maryland, where her cervical tumor was 
diagnosed. This tumor gave rise to the first transformed human cell line, the world-renowned  HeLa cells 131. 
From there on the number of different stable cell lines almost exploded. There are currently 1252 stable cell 
lines from human origin available at ATCC (Manassas, VA, USA), one of the biggest suppliers for cell lines 
today (May 2018). 
Fig. 12. Vivisection of a pig. Picture from the cover of the 
1565 version of Galens (129 AD – ca. 210 AD) Opera Omnia.
21 
 
1.4.2.1 Hepatic Cell Cultures 
Regarding the liver, primary human hepatocytes (PHH) are nowadays still considered as the closest cell model 
to the situation in vivo132-134. As these cells freshly derive from the environment of a whole body, they still 
highly express the majority of important functions for the first several days in their new habitat 135-137. This 
main advantage of this model keeps the PHH remaining as gold standard in the field of pharmacology and 
toxicology. 
Arguably, the main disadvantage of PHHs is their intrinsic variability, as they are obtained from different 
individuals with possible genetic polymorphisms, different hormonal status, diet, age, social habits, and 
exposure to different xenobiotics. Moreover, it is difficult to retain their expression levels of proteins for a 
longer period. Lastly, a problem mostly affecting academic researchers is their high cost and the limited 
accessibility to fresh cultures 138. Today, cryopreservation is the only method for long-term storage and 
therefore permanent availability. This method, however, can influence the cells negatively for the purpose of 
drug metabolism studies 139.  
The development of cell lines derived from tumors gave a highly reproducible and cheaper method to the hands 
of scientists. These cell lines grow continuously with a very high proliferation capacity in a highly reproducible 
manner and have a virtually unlimited life span 140. They are therefore extensively used for countless 
investigations and applications. Despite those economic and simplicity advantages, tumor derived cells have 
limited or altered functions in many ways, as for example liver hepatoma cell lines, which have significant 
lower performances in drug metabolism 132,137. 
1.4.2.2 Models Used in this Thesis 
The work in this thesis was done exclusively with material derived from livers. Two liver cell lines, discussed 
below, as well as isolated mitochondria from mouse livers were used. The cell lines are from human origin 
and well-established within our own lab. Mitochondria, on the other hand, were retrieved from mouse livers. 
Although mice exhibit significant species-dependent differences to humans, this model factually proofs to be 
practical, as FA metabolism is highly conserved throughout mammalians 41. 
1.4.2.2.1 HepG2 Cells 
HepG2 cells are likely one of the most used hepatoma cell lines, to date 141. It is 
the best-characterized hepatoma cell line from human origin with an enormous 
number of data on the effects of hepatotoxic compounds 142. Notably, this cell line 
is very often used in FA metabolism studies because of its expression of many 
differentiated hepatic functions 143. Other than a high mitochondrial activity, this 
includes substantial activities of crucial elements in the metabolism of lipids, like 
synthesis and excretion of lipoproteins and bile acids144, other plasma proteins145, 
Fig. 13. Light microscope 
picture of HepG2 cells in a 
culture flask, one day after 
seeding. 
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intact insulin-signaling146, as well as lipid-storage 147. Gómez-Lechón et al. could nicely show the very similar 
behavior in lipid accumulation of HepG2 cells and PHH 148. The mayor drawback of these cells, however, is 
the poor expression of phase I and phase II drug metabolizing enzymes137,141 often leading to false predictions 
about metabolism-dependent toxicity. Nevertheless, HepG2 cells are a very convenient and powerful tool 
under the right conditions and investigations. 
1.4.2.2.2 HepaRG Cells 
HepaRG cells are a more sophisticated, well-known human hepatoma cell line, derived from a liver tumor of 
a female patient. The researchers Rumin and Gripon (hence the name HepaRG) isolated and characterized the 
cells, starting in 1999 149. A remarkable feature is that these cells, when seeded at low density, transdifferentiate 
into bi-potent hepatic progenitor cells under the right conditions, as used in this work. They then actively divide 
before acquiring typical morphological characteristics of hepatocytes in primary culture. After two weeks at 
confluence and the presence of corticosteroids and dimethyl sulfoxide (DMSO), they build hepatocyte-like 
colonies, which are surrounded by biliary-like cells 150,151. HepaRG cells express 81 – 92% of genes active in 
PHH152 and have a much higher cytochrome P450-activity compared to other hepatoma cell lines 137,150,153.  
Although, this model is more labor- and time-intensive, it gains more and more importance. Because of its 
similar response to PHHs, it is one of the most useful hepatoma cell lines to date for the research of hepatotoxic 
compounds 132,153. 
 
1.4.2.2.3 Isolated Liver Mitochondria 
As described earlier, mitochondria are in constant interaction with the intracellular matrix. Therefore, the 
separation of mitochondria from other cell components can be a useful way to assess effects purely on 
mitochondria under precisely controlled conditions 154. This allows for example to show direct effect on the 
activity of oxidative phosphorylation155, β-oxidation156, mitochondrial membrane potential157, or mitochondrial 
superoxide production158, to give a few examples. Furthermore, mitochondria can be isolated from different 
tissue and species, as for example from genetically 
modified animal models 159. Considering mitochondria 
derived from liver tissue, there are several advantageous 
circumstances. It is a soft tissue with high mitochondrial 
content, which makes the isolation procedure relatively 
easy and results in a good yield. Furthermore, availability 
Fig. 14. Light microscope 
picture of HepaRG cells in 
culture plates. a) Undifferenti-
ated HepaRG cells three days 
after seeding. b) Fully differen-
tiated HepaRG culture four 
weeks after seeding, with 
differentiated structures visible.
a) b) 
Fig. 15. Excised liver of a 
mouse. In preparation for the 
isolation procedure of mito-
chondria, the liver was 
previously flushed with ice-
cold isolation buffer, for fast 
temperature decrease and in 
order to remove blood. 
Hexagonal liver lobules are 
therefore nicely visible. 
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of liver tissue from experimental animals is usually assured, when an animal facility is present. Once isolated, 
mitochondria can be used in two ways. When using the mitochondria on the same day of isolation, they retain 
coupling and integrity over several hours, allowing studies reliant on the membrane potential and transport 
mechanisms. Freezing and thawing mitochondria will disrupt said integrity, allowing the study of effects on 
single enzymes separated from eventual dependence on other factors. 
The most used way to isolate mitochondria is through differential centrifugation. The method was developed 
in the 1950s and has been modified in many ways 160. Nowadays, additional methods have been developed, 
such as preparation of an isopycnic gradient, followed by ultracentrifugation or isolation by magnetic 
microbeads. Although the differential centrifugation method results in a good yield of functionally intact 
mitochondria, contaminations of other organelles, which are mostly peroxisomal161, can interfere with 
proteomic analyses, for example 162. For FA metabolism studies or measurements of oxidative 
phosphorylation, the crude mitochondrial fractions obtained, using differential centrifugation, however, are 
qualitatively sufficient 160. 
1.5 Drugs 
During the work on this thesis, several compounds – pharmaceutical drugs, as well as compounds intended for 
scientific investigations – were used and will be described in this section. 
1.5.1 Model Inhibitors 
As described in Paper 1 and 3, the four following compounds were solely used as models to compare because 
of their well characterized properties. All of them are active as inhibitors in a step of FA breakdown. Important 
for our investigations, using these compounds, was that they were reported in literature to be specific inhibitors 
for only one enzyme type 163. 
1.5.1.1 Etomoxir 
Etomoxir, or (2-[6-(4-chlorophenoxy) hexyl]-oxirane-2-carboxylate, is a specific and powerful inhibitor of 
CPT1. It first has to be activated to etomoxiryl-CoA, before it can bind and irreversibly inhibits its target 
protein.  Reported IC50 values are in the nM range for CPT1 and around 100 times higher for other acyl 
transferases 164,165. Because etomoxir works on CPT1, it only inhibits FA oxidation in intact mitochondria. 
Etomoxir was originally developed for its hypoglycemic properties. By 
inhibiting FA oxidation, it shifts the metabolism towards glucose 
oxidation. After failing for the treatment of diabetes mellitus, it was 
recognized for the treatment of congestive heart failure, however, it was Fig. 16. Chemical structure of etomoxir. 
24 
 
not pursued further. A reconfirmation study with 360 subjects had to be stopped because of suspected 
hepatotoxicity 166.  
1.5.1.2 Methylene Cyclopropyl Acetic Acid 
Jamaican vomiting sickness is an endemically occurring poisoning with a high mortality rate. The poisoning 
leads to pronounced hypoglycemia with symptoms of severe vomiting, usually followed by convulsion, and 
coma. The toxin responsible, hypoglycin, is found in the unripe fruits of the local akee tree, which are mostly 
ingested by children 167.  
Methylene cyclopropyl acetic acid (MCPA) is the active 
metabolite of hypoglycin and is also activated to its CoA-form 
within cells. After its identification, MCPA was studied on its ability of lipid metabolism inhibition. It was 
found that MCPA irreversibly inhibits acyl-CoA dehydrogenases, which are responsible for the first step in β-
oxidation. Specifically, MCPA is able to inhibit short-chain and medium-chain acyl-CoA dehydrogenase, as 
well as isovaryl-CoA dehydrogenase to a lesser extend 168-170. 
1.5.1.3 4-Bromocrotonic Acid 
Similar to MCPA, 4-bromocrotonic acid (4bc) was synthesized and studied for its potential as hypoglycemic 
drug, as well as for the use as research tool for studying β-oxidation 171,172. 
4bc enters mitochondria directly, is then activated to its CoA-form and metabolized to 3-keto-4-bromobutyryl-
CoA by acyl-CoA hydratase and 3-OH acyl-CoA dehydrogenase. This metabolite, then, irreversibly inhibits 
3-ketoacyl-CoA thiolase, as well as acetoacetyl-CoA thiolase 
172,173, therefore stopping β-oxidation at its last step. 
1.5.1.4 Triacsin C 
Triacsin C was included in Paper 3, after it was observed that the 
drugs of investigation were inhibitors for ACSLs. Triacsins were 
found during a screening of bioactive compounds from 
microorganisms. Their strong inhibitory activity on ACSLs was found in 1986 after isolation from a 
Streptomyces species, originating from a Japanese soil sample 174. Of all triacsin compounds (A –D), triacsin 
C was found to be the strongest inhibitor, with an IC50 value of 9 µM on isolated rat liver ACSLs 175. In human 
tissues, however, triacsin C seems to be even more potent, as effective treatment concentrations range around 
1 - 5 µM 176-178. 
Since its discovery, triacsin C has often been used as model compound for the inhibition of ACSL 179-182. 
During these studies, it was found that triacsin C is not affecting all ACSL isoforms the same. It is reported, 
Fig. 17. Chemical structure of 
methylene cyclopropyl acetic 
acid. 
Fig. 18. Chemical structure 
of 4-bromocrotonic acid. 
Fig. 19. Chemical structure of triacsin C. 
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that mostly lipogenic ACSL isoforms are affected (ACSL1, ACSL3, and ACSL4), resulting in the inhibition 
of de novo synthesis of TGs by around 75% and β-oxidation only by around 35% 38. Additionally, unlike the 
other model inhibitors used in this thesis, triacsin C is a competitive inhibitor. 
1.5.2 Selected Compounds for Comparison Investigations 
The following drugs were chosen for Paper 1 for proof of concept and also the elucidation of mechanisms 
leading to steatosis in patients, which come in contact with these compounds. 
1.5.2.1 Amiodarone 
Amiodarone was approved in the US in 1985 as an effective agent for the treatment of tachyarrhythmias 183. It 
showed toxicities on several tissues and received a black box warning in the US after some years 184. 
Amiodarone is a well-known hepatic toxicant with multiple actions, mainly affecting mitochondria.  
Approximately 25% of treated patients show elevation of ALT levels, with 1- 3% of patients developing severe 
hepatotoxicity. Hepatic steatosis is a common finding in such patients 185,186. This kind of injury can be 
explained by its numerous adverse effects on the liver, where 
amiodarone is reported to uncouple oxphos, leading to accumulation 
of superoxide anions, inhibiting β-oxidation, inhibiting ETC 
proteins, and also inhibiting several CYPs 157,187,188. Furthermore, the 
liver may be a preferential target for amiodarone-induced toxicity, 
because higher concentrations in hepatic tissue are reported, due to 
accumulation of this lipophilic compound in membranes 189. Plasma levels can reach 2.5 µM or more190, which 
makes the toxic effects, seen with an only two fold higher concentration in in vitro experiments, highly 
translatable 157,187. 
1.5.2.2 Tamoxifen 
In the late 1950s tamoxifen, then ICI 46 474, was developed in the laboratories of Imperial Chemical Industries 
Ltd. (now AstraZeneca) for the use as a contraceptive 191. Years later, after failing in the intended indication 
and after extensive trials, tamoxifen was finally approved by the FDA for the treatment of breast cancer in 
1977. Because of its availability and inexpensiveness it eventually gained worldwide popularity as a miracle 
drug for breast cancer 191,192. As stated above, tamoxifen, although a first generation SERM, is still used 
extensively in clinics 191.  
Fig. 20. Chemical structure of amiodarone. 
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Despite being generally well tolerated, it has an 
extensive list of adverse reactions, such as higher risk 
for developing endometrial cancers, hot flushes, 
problems with metabolism and eating, elevation of 
serum TG, headaches, liver cholestasis and also 
steatosis, just to name a few 193. In Paper 1, the focus, 
among others, lied on the hepatotoxicity of tamoxifen. 
The most encountered form of tamoxifen-induced 
hepatotoxicity is the development of steatosis. It is even reported that 43% of patients develop hepatic steatosis 
within the first two years of treatment 194. The investigations on the mechanism behind it, however, are still 
ongoing. 
Pharmacological studies of tamoxifen suggested that it gets metabolized to three active metabolites, two of 
which are 100 times more potent than the parent drug 191. Cytochrome P450 3A4 and 2D6 are involved in this 
conversions 104. It is indicated that the pharmacological and toxicological activity of tamoxifen mainly occurs 
via the metabolite 4-hydroxy tamoxifen and its desmethyl analogue endoxifen (Fig. 21b) 191. This is of 
importance for the interpretation of concentration-toxicity correlations and translatability to the in vivo 
situation, as HepG2, which were used for this study, have almost no activity of CYP 2D6. 
1.5.2.3 WIN55, 212-2 
The third test compound, we included in Paper 1, was WIN55, 212-2 (WIN55). It is an aminoalkylindole-type 
CB receptor agonist, developed by Sterling-Winthrop Inc. As explained earlier, the endocannabinoid system 
has an important function in the regulation of hepatic lipid metabolism and is reliant on signaling by 
endocannabinoids like anandamide. There are several xenobiotics affecting this system. One of them is 
WIN55, which is about five times more potent, than trans-Δ9-tetrahydrocannabinol (THC) or Cannabidiol 87, 
the main active substances in Cannabis sativa.  
Marijuana (Cannabis Sativa and preparations from it) is the most commonly used 
illicit drug  consumed in the US 195, as well as in other western countries, like 
Switzerland 196. In 2007 11.2% of adults were consuming this drug at least every 
six months, with 31.7% of them consuming every week and 9.3% every day197. 
In recent years, new insights were made on the consequences of altered CB 
signaling on lipid metabolism. CB1 receptor activation has been consistently 
linked to the initiation and progression of steatosis 90,92,198,199. A study by Hezode 
et al., for example, identified daily cannabis smoking as a novel independent 
predictor of steatosis severity during chronic hepatitis.89 Furthermore, CB1 receptor activation was shown to 
dose-dependently increase the lipid accumulation in HepG2 cells and immortalized primary human 
hepatocytes in the presence of oleic acid 200. 
Fig. 21. Chemical structures of a) tamoxifen and its 
metabolite b) N-desmethyl-4-hydroxytamoxifen (endoxifen). 
a) b) 
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Fig. 22. Chemical structure of 
WIN55,212-2. 
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WIN55 binds both to CB1 and CB2 receptors in the nM range and can therefore be a good surrogate for THC, 
which is only available with special permissions in Switzerland.  
1.5.4 COMT Inhibitors 
Parkinson’s disease is the second most common neurodegenerative disorder, affecting almost exclusively the 
elderly population. It is characterized by the degeneration and loss of dopaminergic neurons, which results in 
disruption of motor functions, leading to tremor, bradykinesia, and rigidity 201. 
The intracellular enzyme catechol-O-methyltransferase (COMT), which is widely distributed in the body, is 
responsible for the elimination of catechol compounds, like dopamine, adrenaline and related substances. 
Inhibition of this enzyme in conjunction with levodopa treatment effectively increases dopamine levels in the 
brain, improving symptoms of Parkinson’s disease. COMT inhibitors are beneficial for Parkinson’s treatment, 
because they decrease the overall elimination of levodopa, improve the delivery to the brain, and prolong the 
clinical response to levodopa treatment 202. These inhibitors are always used in combination with levodopa and 
a DOPA decarboxylase inhibitor 203. 
1.5.3.1 Tolcapone 
The second generation COMT inhibitor tolcapone was developed in the late 1980s, after the first generation 
compounds had failed clinical implementation because of their toxicity. Tolcapone, currently on the market in 
many countries, has a nitrocatechol structure and inhibits COMT reversibly in the periphery and the brain. It 
has a bioavailability of 60% and is always given three times daily to reach steady state, as it has a relatively 
short half-life of 2.1 h 204.  
In preclinical safety studies, tolcapone proved to be safe after toxicity testing in 
several animal species. Clinical trials showed side effects, mainly associated with 
levodopa treatment, meaning dopaminergic adverse events. After about one year 
on the market, tolcapone was finally found to induce liver toxicity, with three fatal 
cases reported. Thereafter it was taken from the market in many countries and only 
reintroduced with restricted use and simultaneous therapeutic drug monitoring 205.  
To this date, available research articles connect tolcapone-associated hepatotoxicity mainly to mitochondrial 
energy metabolism, focusing on uncoupling of oxphos 206-209. Two studies, a biomarker screening210 and a 
capture compound mass spectrometry study211, have implemented the toxicity of tolcapone not only with 
enzymes of oxphos, but also the lipid metabolism. As there are reports of hepatic steatosis in patients with 
adverse reactions under tolcapone therapy 209,212, investigations on possible adverse reactions on hepatic lipid 
metabolism seemed compelling. 
Fig. 23. Chemical structure 
of tolcapone. 
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1.5.3.2 Entacapone 
Entacapone was developed together with tolcapone and is also a second 
generation, reversible COMT inhibitor. It has a lower bioavailability (35%), 
longer half-life (3.4 h) and in contrast to tolcapone, only inhibits COMT in the 
periphery. Entacapone is better tolerated in patients, however, has a greater 
variability of plasma levels during the day (up to ten fold 213), because of its low 
bioavailability, higher clearance, and smaller volume of distribution 204.  
While tolcapone leads to elevated liver enzymes in 3% of treated patients, entacapone only affects 0.2% 202,214. 
It is, however, also associated with interactions with proteins of oxphos and lipid metabolism 210,211. 
Furthermore, entacapone was also associated with mitochondrial uncoupling, but at higher concentrations than 
tolcapone 207. 
Even though entacapone has a lower incidence of toxicity than tolcapone, it is clearly linked to possible adverse 
effects on mitochondrial energy metabolism. Additionally, because of its similar chemical structure, we also 
included this compound in our studies for toxicological comparison to tolcapone. 
 
1.6 Aims of the Thesis 
1.6.1 General Aims 
The main goal of the thesis was to contribute to the understanding of idiosyncratic drug-induced steatosis 
observed in clinics. Therefore, we aimed to create a cell model for impaired hepatocellular FA metabolism and 
to evaluate biomarkers for FA metabolism inhibition. Secondly, we aimed to elucidate mechanisms behind the 
idiosyncratic adverse reactions of drugs, leading to steatosis, using the methods established in the first step of 
Paper 1.  
To achieve this goals, three major work packages were defined as followed. 
1.6.2 Paper 1 (Acylcarnitines as Biomarkers) 
In the first step, we wanted to find and characterize biomarkers for changes in FA metabolism by evaluating 
acylcarnitines as specific biomarkers for distinguishable locations of inhibitions within the FA catabolism 
pathways. We aimed to establish and optimize a semi-quantitative acylcarnitine measurement using LC-
MS/MS, with three specific and well-established inhibitors of FA oxidation. We compared, as well as 
Fig. 24. Chemical structure 
of entacapone. 
29 
 
supplemented, the results of the new method with older, well established methods. In a second step of the 
study, we applied the same methods on three compounds, of which adverse reactions are not well understood, 
to obtain new insights about their steatogenic mechanisms. 
1.6.3 Paper 2 (Tolcapone and Entacapone – Fatty Acid Metabolism) 
The purpose of the second project was the detailed study on the mechanistic bases of the steatogenic effect, 
exerted by tolcapone treatment, to further increase the understanding of its adverse reactions on the FA 
metabolism. Entacapone, also a second generation COMT inhibitor, was included as well, because of its 
structural similarity. Also, we used HepaRG cells in this investigation to further establish the acylcarnitine 
measurement from Paper 1, as means for a detailed analysis of FA metabolism changes in an additional cell 
line.  
1.6.4 Paper 3 (Tolcapone and Entacapone – Electron Transfer Chain) 
The focus of Paper 3 was to expand the knowledge of tolcapone-associated steatosis and liver toxicity observed 
in clinics. Entacapone was included as well, as in the previous Paper. Tolcapone, a known mitochondrial 
uncoupler, was shown to also interact with proteins of the ETC besides its impact on FA metabolism. To study 
this additional important effects, we therefore aimed to additionally investigate their actions in regard to their 
effect on mitochondrial respiration, as well as cell death for a comprehensive study about the drugs.  
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Legends to supplementary Figures  
 
Supplementary Figure 1  
Chemical structures of etomoxir, methylenecyclopropylacetic acid (MCPA), 4-bromocrotonic acid (4-BCA), 
amiodarone, tamoxifen, and WIN55,212-2.  
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Supplementary Figure 2  
Effect of etomoxir, methylenecyclopropylacetic acid (MCPA) and 4-bromocrotonic acid (4-BCA) on plasma 
membrane integrity and on the cellular ATP content. HepG2 cells were exposed to the toxicants for 24 h. 
Membrane integrity is expressed as the percentage of dead cells with Triton X set at 100%. ATP content is 
displayed as the percentage in relation to control incubations (DMSO 0.1%) set at 100%. (A,B) etomoxir, 
(C,D) MCPA, (E,F) 4-BCA. Results are given as mean ± SEM in relation to control incubations (DMSO 
0.1%).*p<0.05 vs. DMSO 0.1% control.  
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Supplementary Figure 3  
Effect of amiodarone, tamoxifen and WIN55,212-2 on plasma membrane integrity and on the cellular ATP 
content. HepG2 cells were exposed to the compounds of interest for 24 h. Membrane integrity is expressed as 
the percentage of dead cells with Triton X set at 100%. ATP content is displayed as the percentage in relation 
to control incubations (DMSO 0.1%) set at 100%. (A,B) amiodarone, (C,D) tamoxifen, (E,F) 4-WIN55,212-
2. Results are given as mean ± SEM in relation to control incubations (DMSO 0.1%).*p<0.05 vs. DMSO 0.1% 
control.  
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Supplementary Figure 4  
Effect on the dicarboxylic acid concentration in HepG2 cells. Dicarboxylic acids were analyzed in HepG2 
cells treated with the compounds of interest for 24 h using LC-MS/MS as described in Methods. Results were 
normalized to the values obtained in DMSO 0.1% exposed control cells. Values are expressed as mean ± SEM. 
*p<0.05 vs. DMSO 0.1% control.  
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Supplementary Tables 
 
Supplementary Table 1 
Primers used for mRNA quantification. 
ACC: forward 5’-CGA GGG AGA AGG TAG CAC TG-3’, backward 5’-GAA ACC ACG GAG CAG 
AAG AG-3’ 
ACSL1: forward 5’-GGA GTG GGC TGC AGT GAC -3’, reverse 5’-GGG CTT GCA TTG TCC CTG 
T-3’ 
ACSL5: forward 5’-GCT CCT TTG AGG AAC TGT GC-3’, reverse 5’-ATC CCC GAG TCC CAT AAA 
AC-3’ 
ApoB: forward 5’- AAG GCT TCA AGC ACA TTG GT-3’, reverse 5’- CTG AGC CTC CAG ACC CAT 
C-3’ 
CD36/FAT: forward 5’- TGC TAG AGA CCC TGG CTG AT -3’, backward 5’- CAG CGT CCT GGG 
TTA CAT TT -3’ 
Cidea: forward 5’-GCG TCC TTC CAA CCA CTT TT-3’, backward 5’-ACA GAG ACC CCA CAC 
AGA TG-3’ 
FAS: forward 5’-AAC TCC TGC AAG TTC TCC GA-3’, backward 5’-GCT CCA GCC TCG CTC TC-
3’ 
FATP5: forward 5’- ACG GGG AGA AGT TGT ACC AG -3’, backward 5’- CAG TTT GAA CGT GCT 
GGT GA -3’ 
GAPDH: forward 5’-AGC CAC ATC GCT CAG ACA C-3’, reverse 5’-GCC CAA TAC GAC CAA ATC 
C-3’ 
SREBP-1c: forward 5’-TGT TTC CGT CTG CCT CTT CT-3’, backward 5’-GTG AGC CTG TCT CCT 
TCT GG-3’ 
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Legends to supplementary Figures 
 
Supplementary Fig. 1.  
Effect on intracellular lipid accumulation in HepG2 cells. Cells were first cultured for 24 h in a medium 
containing BSA-bound palmitate and oleate before treatment with the compounds of interest for 24 
h. After treatment, cells were fixed, stained with DAPI for nuclei (blue) and BODYPI 493/503 for 
neutral lipids (green), and analyzed with fluorescence microscopy. Abbreviation: Ctrl: control (DMSO 
0.1%). 
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Supplementary Fig. 2 
Effect of tolcapone and entacapone on fatty acid metabolism in freshly isolated mouse liver 
mitochondria. Mitochondria were treated with the toxicants for 10 min before determining (A) 
metabolism of 14C-palmitic acid (control activity 3.85±0.2 nmol x min-1 x mg protein-1), (B) 14C-
palmitoyl-carnitine (control activity 11.0±0.7 nmol x min-1 x mg protein-1), (C) 14C-palmitoyl-CoA 
(control activity 1.96±0.10 nmol x min-1 x mg protein-1) and (D) the activity of long-chain acyl-CoA 
synthetase (ACSL) (control activity 1.72±0.09 nmol x min-1 x mg protein-1). Results are presented as 
mean ± SEM of at least 6 independent experiments. *p<0.05 vs. DMSO 0.1% control. 
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Supplementary Fig. 3.  
Activities of long-chain- and medium-chain-acyl-CoA dehydrogenase in mouse liver mitochondria. 
Disrupted mitochondria were acutely treated for 5 min before assessing the activities of (A) long-
chain-acyl-CoA dehydrogenase and (B) medium-chain-acyl-CoA dehydrogenase. Basal activities 
were 40.2 ± 1.4 nmol x·min-1 x·mg protein-1 for the long-chain-acyl-CoA dehydrogenase and 19.2 ± 
1.1 nmol x min-1 x·mg protein-1 for the medium-chain-acyl-CoA dehydrogenase. Results were 
normalized to control values (DMSO 0.1%) and are presented as mean ± SEM. *p<0.05 vs. DMSO 
0.1% control. Abbreviations: Ctrl: control (DMSO 0.1%), Tol: tolcapone, Enta: entacapone, TC: 
triacsin C. 
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Supplementary Fig. 4.  
Western blots of proteins involved I hepatic lipid metabolism. Whole cell lysates were subjected to 
western blot analysis as described in Methods. Shown are representative blots of the investigated 
proteins. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used for normalization and 
loading control. Abbreviations: CON: control (DMSO 0.1%), Tol: tolcaptone, TC: triacsin C, Enta: 
entacapone, ACSL: long-chain acyl-CoA synthetase, FABP: fatty acid binding protein, ADRP: 
adipose differentiation-related protein, GPAT1: glycerol-3-phosphate acyltransferase 1, MTTP: 
microsomal triglyceride transfer protein. 
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Table 
Supplementary Table 1 
The following primers were used for mRNA quantification: 
GAPDH fwd: 5’-AGCCACATCGCTCAGACA-3’ 
  rev:  5’-GCCCAATACGACCAAATC-3’ 
SOD1  fwd: 5′-TGGCCGATGTGTCTATTGAA-3′ 
  rev:  5′-ACCTTTGCCCAAGTCATCTG-3′ 
SOD2  fwd: 5′-GGTTGTTCACGTAGGCCG-3′ 
  rev:  5′-CAGCAGGCAGCTGGCT-3′ 
NRF2  fwd: 5’-AGCCCAGCACATCCAGTCAG-3’ 
  rev:  5’-TGCATGCAGTCATCAAAGTACAAAG-3’ 
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3. DISCUSSION 
 
Drug-induced adverse reactions are not only agonizing for patients but also challenging for clinicians. Adverse 
reactions, aside from monetary consequences for the healthcare system, also represent a crucial challenge to 
the industry in the success of bringing and maintaining a drug on the market. DILI is the main reason for drug 
withdrawal from the market 215 and is, especially in the case of idiosyncratic reactions, rarely detected in 
preclinical or even clinical development 124. Additional to withdrawal, marketed drugs can also receive black 
box warnings or restricted use assignments. An improved preclinical detectability of such adverse reactions 
would therefore be highly appreciated in the industry. 
The low incidence of idiosyncratic DILI, coupled with unpredictability and the incomplete understanding of 
various mechanisms of action, documents the need of additional investigations on this topic. In recent years, 
research has shown that DILI is not only dependent on the drug itself, but also on several environmental and 
host factors 108. Particularly, preexisting or acquired mitochondrial predispositions have increasingly been 
identified as susceptibility factor for the development of idiosyncratic adverse reactions 216. 
With our newly established method for the measurement of changes in FA metabolism by analyzing the 
acylcarnitine pattern, we aimed to provide a sensitive biomarker to improve the detection and investigation of 
drug-induced hepatic steatosis. 
3.1 Acylcarnitine Measurement 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a highly sensitive method for the specific 
analysis of multiple compounds in one sample. The analysis of acylcarnitines for the investigation of FA 
metabolism has been used since many years 217. Relying on radioenzymatic assays at first, it was promptly 
adopted in clinics for the diagnosis of organic acidurias and FA oxidation defects after development of 
respective LC-MS/MS methods 218. Nowadays, most countries adopted the measurement of medium-chain 
acylcarnitines in the routine-screening of newborns, in order to test for MCAD deficiency 219. 
Since acylcarnitines are known to reflect the cellular acyl-CoA pattern 64, we aimed to use the identification of 
altered acylcarnitine profiles to make interpretations based on specific intermediate metabolites. In Paper 1, 
we included C2-, C4-, C5-, C6-, C8-, C10-, C12-, C14-, C16 carnitines in our LC-MS/MS method, giving us 
insight into chain-length specificity of FA oxidation inhibition. Furthermore, we included a specific 
intermediary metabolite, 3-oxo palmitoyl-CoA, in order to get information about the last step of β-oxidation. 
To develop and simultaneously test the method, we included three well specified inhibitors of FA oxidation. 
For the most part, we found anticipated changes, showing nicely the applicability of this effective method. 
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This is nicely visible by the intense increase of medium-, but not long-chain acylcarnitines after treatment with 
MCPA, a strong MCAD inhibitor. The rise of medium-chain acylcarnitines is well known in patients lacking 
a functional MCAD 220,221. Furthermore, acetylcarnitine, as well as long-chain acylcarnitines were significantly 
suppressed by MCPA, indicating the lack of substrate for the β-oxidation of short-chain FAs. For the cell, 
acetyl-CoA is not only important for anabolic reactions, but is also a central messenger for the fine tuning of 
energy metabolism and can be interpreted as part of the overall energy-status of the cell 222. Since part of the 
acetyl-CoA pool is constantly converted to acetylcarnitine 223, the cellular content thereof could also be 
understood in this way. 
Interestingly, however, the decline in acetylcarnitine was not reflected in the intracellular ATP content. This 
could be explained by the fact that the cells are grown in culture medium, containing 5.5 mM glucose, and 
therefore able to compensate deficient energy production by acetyl-CoA usage, by an increase in the use of 
glucose. This effect can be caused by the depletion of cytosolic acetyl-CoA, which activates AMPK, and 
thereby stimulates katabolic reactions, such as stimulation of glycolysis 222,224.  
In the case of etomoxir-induced changes, we observed a decrease in C8- to C16 acylcarnitines in the 
supernatant, with normal levels of acylcarnitines shorter than C6. This pattern was expected, due to the inability 
of the cell to convert activated long-chain FAs into acylcarnitines as a result of CPT1 inhibition. Indeed, there 
is also an acyltransferase form present, which is not associated with mitochondria, the carnitine-octanoyl 
transferase (COT). This microsomal- and peroxisomal-associated enzyme, although having a preference for 
medium-chain acyl-CoAs, is also able to transfer long-chain acyl-CoAs to carnitine. Studies by Lilly et al. 
showed that etomoxiryl-CoA also reversibly inhibits COT, however, at 100 times the concentration it needs 
for CPT1 inhibition 165. 
Triacsin C induced similar changes to the acylcarnitine profile of treated cells as etomoxir. The suppression of 
all acylcarnitines, but acetyl- and C4-acylcarnitines, can be explained through a similar mechanism as the one 
of etomoxir. When FAs cannot be activated to the CoA-form, it is impossible for carnitine acyltransferases to 
interact with them, thus leading to a decreased overall content of acylcarnitines. Since there are up to 26 
isoforms of acetyl-CoA synthetases, with eleven of them responsible for medium-chain and long-chain FA 
activation 39, it also seems comprehensible that acylcarnitines were less suppressed than in etomoxir-treated 
cells, as triacsin C reportedly only inhibits certain isoforms, and not the whole activation process 180. 
Treatment with 4-bromocrotonic acid led to a somewhat unexpected acylcarnitine pattern. The 3-oxo-
palmitoylcarnitine accumulation was induced, as expected from long-chain 3-ketothiolase inhibition. 
However, we also found an accumulation of C5- and C4-carnitines. This suggests that 4-bromocrotonic acid 
is not specific for the long-chain form of the β-ketothiolases, but that it also inhibits the short-chain form 
(acetoacetyl-CoA thiolase). This effect could be deduced from the structure of this compound, as it has the 
same form as butanoyl-CoA (C4-CoA), with an additional bromine at the fourth carbon. Furthermore, 4-
bromocrotonic acid first has to be hydroxylated and then dehydrogenated to 4-bromo-3hydroxybutanoic acid 
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and 4-bromo-3oxobutanoic acid, respectively, to finally yield the form, which is responsible for the inhibition 
of the thiolases 172,173 . As these conversions are carried out by enzymes of the β-oxidation chain, namely enoyl-
CoA hydratase and 3-hydroxy acyl-CoA dehydrogenase, it would be plausible that 4-bromocrotonic acid also 
could inhibit at these steps. Studies on isolated enzymes by Olowe and Schulz, however, found no inhibitory 
activity on the 3-hydroxyacyl CoA-dehydrogenase and only a minor (8%) inhibition of the long-chain enoyl-
CoA hydratase with concentrations of 4-bromocrotonic acid, which inhibited 100% of both short- and long-
chain 3-ketothiolases 173. Taken together, these findings are in agreement with our interpretation of the 
acylcarnitine pattern and the conclusion that 4-bromocrotonic acid inhibits both forms of mitochondrial acyl-
CoA thiolases. 
Regarding these four model compounds, the established LC-MS/MS method proved to supply valuable and 
discriminative information on the location of inhibition. Furthermore, the method repeatedly turned out to be 
a more sensitive approach to identify drugs inhibiting FA oxidation.  
Of the ten compounds, on which this method was applied, the acylcarnitine method proved to show significant 
findings at lower concentrations in half of the cases (tamoxifen, WIN55, tolcapone, entacapone, and valproic 
acid). For two compounds (MCPA and amiodarone) the method was equally sensitive as the radioenzymatic 
assay and for two (etomoxir and triacsin C) the tested concentrations did not allow to make this comparison. 
Only 4-bromocrotonic acid was more potent in β-oxidation inhibition studies, using isolated mitochondria, 
than in producing significant changes in the acylcarnitine pattern. The LC-MS/MS method, however, was still 
more sensitive than the determination of 4-bromocrotonic acid-induced inhibition of β-oxidation in cells. In 
all cases, measurement of β-oxidation inhibition by radioenzymatic- or acylcarnitine determinations was more 
sensitive than lipid accumulation results. 
As stated above, it is of desire for the pharmaceutical industry to have tools, which can predict drug-induced 
hepatic steatosis during preclinical development. Indeed, several steatogenic drug candidates could be 
identified preclinically in animal models 225. However, considering the high costs of animal studies, as well as 
the “three R” principle, new in vitro systems are of high interest. Additionally, in vitro systems can be applied 
in high-throughput screenings, allowing for the testing of large numbers of drug candidates.  
In light of the multiple hit theory, there are four basic pathways in which a “hit” has to occur for the 
development of hepatic steatosis, which is uptake, degradation, synthesis, or excretion. Since all these 
pathways are very complex and underlie various regulatory and compensatory factors, tests, which give more 
information of what exactly is affected, would be of advantage. The acylcarnitine profile measurement, 
obviously, is only focused on the breakdown of FAs.  
Since many years, information about the FA-breakdown capacity of cells or tissues is acquired using 
radioenzymatic assays 226-228. By incubation with radioactive-labelled FAs and subsequent measurement of 
radioactive products by liquid scintillation, this method allows for precise and quantitative results of the 
oxidation capacity of nearly every tissue or cells. The assay can also be adapted to various situations by using 
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differently labelled FAs or FA-metabolites. One can for example supply 14C-palmitate to investigate general 
β-oxidation capacity. By using 14C-palmitoylcarnitine, the activation step, as well as the influence of CPT1 are 
omitted. By using 14C-octanoate, results will give information about enzymes with medium-chain specificity. 
Also the location of the label can influence the outcome of results. 14C-label on the position C-16 allows for 
the measurement of complete oxidation of the FA, while label on the C-1 position is more readily available, 
only showing the first cycle of oxidation. Today, this type of assay is still the standard method to show 
inhibition of β-oxidation 229. 
The drawbacks, however, of these well-established and popular assays are obvious. First of all, although 
relatively safe, 14C is radioactive and requires special safety conditions, such as special allocated working 
spaces and waste management 230. Furthermore, radio-labelled substrates are considerably more expensive than 
their “normal” counterparts. Especially, when in need of different substrates for the evaluation of different 
single-reaction steps, or partial reactions, this can be of significance.  
With the determination of the acylcarnitine-pattern by LC-MS/MS several of these drawbacks are avoided. 
The acylcarnitine method presented in this thesis is not only considerably cheaper per sample, but also safer 
and much faster. Since the assay was optimized for the use in 96-well format, it uses a limited amount of cells, 
and therefore cell culture products, as well as less amount of drugs for treatment. Also the sample workup is 
fast and uncomplicated, as the method was developed without derivatization processes, which are often needed 
in other protocols 231-233. But most importantly, the acylcarnitine-profile gives information about several 
aspects of FA breakdown within one measurement, compared to the radioenzymatic assays. This LC-MS/MS 
method, however, cannot always replace the determinations with radioactive-labelled substrates, as it is only 
semi-quantitative. An additional advantage of the acylcarnitine measurement is that it only needs a small 
amount of supernatant, leaving cells, as well as remaining supernatant available for separate investigations. 
This makes it possible to link several assays together with the use of only one 96-well plate. 
To this date, a limited, but slowly increasing number of quantifiable in vitro models of steatosis for the use of 
early screening of potential pharmaceuticals have been proposed 109,225,234. All of them rely on the colorimetric 
or fluorescent detection of intracellular lipids within treated hepatocytes. Most of these systems use HepG2 
cells for the testing and quantification of lipids, which is done with either Nile red 235, Oil red O 236, or 
BODIPY493/503 147,237 staining. The fluorescent dye BODIPY proofed to be the most sensitive for the 
detection of lipid accumulation in these studies. 
Taking these considerations together, the acylcarnitine-profile analysis seems to be highly suitable for the 
application in research and industry for a detailed assessment of drug-induced FA-oxidation defects. 
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3.2 Mechanisms of Hepatic Steatosis 
The main goal of this thesis was the elucidation of steatogenic mechanisms exerted by the drugs of interest. 
Regarding the compounds, which were chosen for the mechanistic investigations, all of them showed dose-
dependent lipid accumulation in our in vitro models, providing first and important evidence and demonstrating 
the principle usability of the models. 
Concerning the model inhibitors discussed above, we did not find induction of steatosis with etomoxir nor 
with MCPA treatment. This was surprising at first, as these compounds are strong and irreversible inhibitors 
of β-oxidation, and were also applied on cells in concentrations much higher than their EC50 values for FA 
oxidation inhibition. This finding, however, is in line with the multiple hit hypothesis of steatosis-induction, 
which states that multiple factors are necessary for the induction of excess LD formation. In our studies, 
triacsin C even reduced lipid accumulation, determined by flow cytometry and fluorescence microscopy. 
These findings were less surprising, as triacsin C is reportedly inhibiting acyl-CoA synthetases mainly 
involved in lipogenesis 181. Dechandt et al. made similar findings, showing triacsin C to reduce LD formation 
in rat hepatocytes 238. Importantly, these findings mean that impairment of hepatic FA metabolism can be 
missed, if LD accumulation is used as the only assay of FA metabolism. 
Of the model compounds, only 4-bromocrotonic acid showed accumulation of neutral lipids in treated cells. 
Since our data consistently supported the multiple hit theory, it seems obvious that 4-bromocrotonic acid is 
exerting an additional pro-steatogenic effect to its irreversible inhibition of β-oxidation. Explanation thereof 
could be taken from studies by the group of Jim Fong with 4-bromocrotonic treated adipocytes. They found 
an increase in glucose uptake, as well as inhibition of hormone-sensitive lipase, after treatment with the 
compound. Both mechanisms are reportedly independent from FA-oxidation inhibition 239,240. They argue that 
the active metabolite of 4-bromocrotonic acid, 3-keto-4-bromobutyryl-CoA, is accumulating within 
mitochondria, and through either conversion into its carnitine derivate (by the mitochondrial carnitine 
acetyltransferase) and subsequent translocation by the carnitine shuttle, or by diffusion of the free acid (formed 
by short-chain acyl-CoA hydrolase), it reaches the cytosolic compartment, where it inhibits the lipase. The 
hormone-sensitive lipase is also expressed in hepatocytes, where it contributes to lipolysis, which is carried 
out on the surface of LDs 241. The steatogenic effect of 4-bromocrotonic acid in hepatocytes could therefore be 
attributed to β-oxidation inhibition coupled with decreased breakdown of stored TGs.  
3.3.1 Mechanisms of Amiodarone 
Amiodarone is a well-known hepatotoxic compound with high steatogenic potential in patients. Since its 
introduction it has been extensively studied on its adverse reactions on the liver. Accumulation in liver tissue 
242, as well as in mitochondria 243, due to its high lipophilicity, leads to multiple toxic responses in cells. This 
toxicity is attributed to the benzofuran moiety of the molecule 244. 
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Amiodarone is a strong inhibitor of FA oxidation, leading to microvesicular steatosis 245 . It was shown to 
decrease the activities of CPT1 and long-chain acyl-CoA dehydrogenase 187,243,244. Furthermore, it is also a 
known mitochondrial uncoupler, as well as an inhibitor of Complex I and II 243,244, which aggravates the effects 
of β-oxidation inhibition. As inhibition of the ETC, especially at Complex I, leads to increased accumulation 
of ROS, toxicity of accumulating FAs may be further enhanced through the formation of lipid peroxidation 
products. In fact, increased lipid peroxidation is a reported consequence of amiodarone treatment 246.  
The acylcarnitine pattern of amiodarone-treated cells showed a dose-dependent decrease in medium-chain to 
long-chain acylcarnitines (C6-C14), with only a small decrease in palmitoyl-carnitine. CPT1 inhibition, 
however, should yield significant lower levels of palmitoyl-carnitine, as apparent in etomoxir-treated cells. 
This could be explained by the inhibition of long-chain acyl-CoA dehydrogenase by amiodarone, leading to a 
less pronounced decrease of this long-chain variant due to limited accumulation of palmitoyl-CoA. In our 
studies, contrary to an earlier study 187, we also observed inhibition of MCAD, which should result in higher 
content of medium-chain acylcarnitines. Since C6 – C14 acylcarnitines were decreased, it appears that CPT1 
inhibition, decreasing all long- and medium-chain acylcarnitines, is of greater influence on the pattern of 
acylcarnitines than the downstream inhibition of MCAD.  
In a study in mice treated with amiodarone, it was found that amiodarone inhibits the activity of MTTP 247, 
leading to a decreased VLDL export of the liver, with corresponding lower TG concentration in the serum. In 
our study, we also found a decrease in VLDL export in HepG2 cells, which was, however, not significant. 
An additional mechanism of amiodarone augmented hepatic steatosis, reported in literature, is the upregulation 
of many lipogenic genes 248, explained in part by the triple PPARα/β/γ agonism of amiodarone 249. 
Lastly, we also found a decrease in thapsic acid formation in cells treated with amiodarone. Thapsic acid 
represents an intermediate in the peroxisomal breakdown of palmitic acid by ω-oxidation, which can be used 
by the cell as alternative pathway, if mitochondrial breakdown is disturbed 40. This inhibition is not surprising, 
as FAs are metabolized to dicarboxylic acid by the CYP4A and 4F family, and amiodarone and its metabolites 
are known inhibitors of multiple other CYPs 188. 
Altogether, the adverse effects of amiodarone presented from research show remarkably consistently a 
conclusive picture of multiple impacts of the drug on the development of hepatic steatosis. 
3.3.2 Mechanisms of Tamoxifen 
We found tamoxifen to induce lipid accumulation in HepG2 cells, like it is seen in 43% of patients as 
hepatocellular steatosis within the first two years of treatment 194. It inhibited dose-dependently the β-oxidation 
of the cells, at the location of CPT1. This can also be seen in the pattern of acylcarnitines, where acetyl-
carnitine and C6 – C16 acylcarnitines were decreased, consistent with the inhibition of mitochondrial FA 
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import. Measurements of intracellular acyl-CoAs in MCF7 cells (mammary epithelium cells) also revealed 
decreased content of a medium chain acyl-CoA, however, with additional increase in C16-CoA. The study, 
however, showed no effect on acetyl-CoA levels 250, while slightly reduced acetyl-CoA levels were observed 
in the liver of tamoxifen treated rats 251. In addition to β-oxidation inhibition, we also found tamoxifen to 
decrease ω-oxidation, as thapsic acid formation was inhibited. Lastly, further increasing lipid accumulation, 
also VLDL export was decreased by tamoxifen treatment.  
The few in vitro studies on tamoxifen consent on one mechanism leading to steatosis of the cells used, namely 
increased FA and TG synthesis, mediated by the transcription factor SREPB-1c 250,252-254. Furthermore, in one 
of the studies, it was found that tamoxifen increases glycolysis and inhibits Complex I 250. 
The majority of toxicity studies of tamoxifen on the liver were carried out in animal experiments, using mainly 
rats, as this model was shown to be superior to the mouse model 255. The findings and propositions of tamoxifen 
studies vary greatly between research groups 104. For example, the hypothesized steatogenic mechanism 
mediated by SREBP-1c from in vitro experiments was partially confirmed in one study in mice 256, while four 
other groups found the opposite, namely a downregulation of FAS 251,257-259, which is regulated by SREBP-1c 
260.  
In rat liver mitochondria, it was observed that tamoxifen (or metabolites) uncouple mitochondria and 
compromise the ETC 261,262, with the specific location of Complex I, found a few years later 263. Complex I 
inhibition was also seen in mice, in which also Complex IV was inhibited by tamoxifen 257. An investigation 
in isolated rat liver mitochondria, furthermore, showed only inhibition of Complex III and not of Complex I 
or IV 264. For the most part it seems clear, that tamoxifen is disturbing the oxphos pathway, with most reports 
agreeing on Complex I as the affected site. 
Since Complex I regenerates NAD+, which is a cofactor needed for the second dehydrogenation step in β-
oxidation 42, it was hypothesized that the β-oxidation in mitochondria is compromised as well 104. Indeed, we 
found inhibition of CPT1, which is also proposed by other authors 104. One author found CPT1 inhibition with 
a joint decrease of its mRNA 257, while other authors, however, did not find FA oxidation reduction in mice 
256, or an influence on CPT1 activity in rats 251. Also no difference in genes relating β-oxidation in mice was 
reported 256,258, suggesting no inhibition of β-oxidation in vivo. 
Tamoxifen reduced VLDL export in our study, which can also be observed in patients 265. It was argued by the 
authors of this study that this observed change in patients was due to decreased release of growth hormone, 
which in turn decreases ApoB expression. Also one study in mice reported lower serum TG and slightly lower 
ApoB concentrations 257. The state of data concerning ApoB, however, is equally complex as the topics above, 
as also opposite reports can be found. A case report of a woman showed high VLDL and high ApoB in plasma 
266, while other studies report no differences in VLDL levels 267-270. These studies also reported no significant 
change in serum TG levels. In contrast, there are reports saying otherwise, as for example a recent meta-
analysis of five studies with 215 participants, showing an increase in serum TG 271. Another study, showing a 
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significant elevation of serum TG, states that the changes in the vast majority of patients were not clinically 
important, while in a small number of patients, who already presented high TG levels prior to treatment, 
tamoxifen therapy led to further elevations, necessitating dose reduction 272. The significant elevation of serum 
TG could therefore be an adverse effect only affecting a specific population. A study in support of this showed 
a specific ApoE phenotype (ApoE4) to be a determining factor for serum TG elevation in Greek women 269.  
Tamoxifen was also shown to reduce the activity of LPL in several investigations 266,273,274, implicating 
decreased VLDL metabolism in the periphery as a culprit of elevated serum TG. 
The discussion above shows the complex and diverse findings of studies with tamoxifen and suggest numerous 
effects leading to hepatic steatosis. The mostly coherent findings of complex inhibition, with possible reduction 
in FA oxidation, coupled with upregulation of lipogenic genes and reduced VLDL catabolism in the periphery, 
could be taken as mechanisms leading to hepatic steatosis. 
Lastly, the question of metabolite formation in our cell model remains, as tamoxifen, although quite potent 
itself for ESR binding (IC50 around 420 nM 275), is considered as prodrug and needs activation to its 
metabolite 4-hydroxy tamoxifen (endoxifen), which possesses a 100 times higher activity 103,276. Since 
HepG2 cells have almost no activity of CYP2D6 137, which is responsible for this transformation, effects 
observed in vivo or in PHH could be missed. Endoxifen has not only a higher ESR-binding capacity but 
also behaves differently in uncoupling and Complex inhibition studies 261, questioning the translatability 
of in vitro studies with tamoxifen. 
3.3.3 Mechanisms of WIN55, 212-2 
The endocannabinoid system has substantially gained recognition in terms of energy homeostasis. 
Cannabinoids, endogenous and exogenous, modulate appetite behavior, promote adipogenesis, block energy 
expenditure, and regulate peripheral energy metabolism 277,278. Some of the effects originate from the central 
nervous system over tissue innervations, other effects are direct, through binding of CB receptors, present in 
numerous tissues. 
In regard to the liver, it is now widely accepted that CB1 activation promotes hepatic steatosis, while CB2 
activation is considered protective 85,88,90,199,278,279. CB2 is mainly expressed in neuronal cells and immune cells. 
The protective effect on the liver by CB2 is believed to be carried out by anti-fibrotic effects on stellate cells, 
as well as by an anti-inflammatory effect through modulation of Kupffer- and endothelial cells 88. Since CB2 
is not expressed in hepatocytes 280,281, the steatogenic effect of cannabinoids is mediated over hepatic CB1, as 
this receptor is shown to be overexpressed in steatogenic tissue 282. 
For the most part, the nature of cannabinoid mediated lipid accumulation, is not well elucidated, but rather 
shown through inverted mechanistic studies, namely through knockout or inhibition of CB1, as this modulation 
has been considered as possible treatment target 87. Knockout of CB1 in animals or specific inhibition of CB1, 
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consistently led to an increased FA oxidation capacity and also to a resistance to diet-induced hepatic steatosis 
90,91,278,280,283-285. 
The synthetic cannabinoid WIN55 showed β-oxidation inhibition in our study with a decrease in C2-C10 
acylcarnitines, with normal concentrations of C12-C16 acylcarnitines. This pattern could be explained by 
inhibition of mitochondrial import combined with impaired long-chain FA metabolism. We, however, did not 
find direct inhibitory effects of WIN on CPT1 or long-chain acyl-CoA dehydrogenase. In the literature, on the 
other hand, it is reported that there is a downregulation of CPT1 after treatment with THC 92. Other authors 
showed the negative regulation of CB1 on CPT1 by knockout models 91,285,286. Also long-chain acyl-CoA 
dehydrogenase was shown to be upregulated upon antagonism of CB1 285. Since the measurements of 
acylcarnitines, as well as of β-oxidation, were done in an in vitro system over 24 hours and enzyme inhibition 
studies in acutely treated mitochondria, it could be that decreased activities of CPT1 and LCAD were missed 
in our study. 
Cannabinoids act inhibitory on the adenylate cyclase, resulting in reduced cAMP levels, which results in a 
decreased activity of protein kinase A (PKA) 287. This leads to less phosphorylated, and thus less active CPT1 
288. The same mechanism can also derive from decreased activity of AMPK, which is also negatively controlled 
by cannabinoids 96. Enzyme complexes of the ETC are also affected by this decrease in phosphorylation and 
are shown to have decreased activity after treatment with cannabinoids in different tissues 95,97,98,289-291, which 
can also lead to increased formation of ROS 292. This reduced activity of the ETC can therefore also be a factor 
contributing to the decreased FA oxidation, observed with the treatment of WIN55. Furthermore, elevated 
ROS levels in hepatocytes can worsen the development of hepatic steatosis as well. The cell upregulates 
mitochondrial biogenesis under circumstances of mitochondrial stress, to promote a healthy, functional 
mitochondrial pool 293. Studies in adipocytes showed a clear negative effect on mitochondrial biogenesis 
through down modulation of PGC1α 294,295, which further fuels mitochondrial dysfunction, as seen with 
treatment of CB1 agonists. 
Another contributing mechanism for lipid accumulation is the induction of lipogenic factors, such as SREBP-
1c, ACC or FAS. Upregulation, higher expression, and also higher activities of these factors are reported in 
almost every study investigating cannabinoid-induced changes in lipid synthesis 92,200,277,280,285. 
Moreover, it was shown that CB1 activation contributes to diet-induced insulin resistance through inhibition 
of insulin signaling. This insulin resistance impairs suppression of hepatic glucose production, while de novo 
lipogenesis stays the same or even increases due to compensatory hyperinsulinemia 296. 
Additional to the ubiquitous actions of cannabinoids in the body, a circumstance that makes it difficult to draw 
conclusions from literature and to translate in vitro findings, is that studies are done in numerous species and 
tissues, mostly focusing on neuronal implications. In this discussion references contain studies carried out in 
tissue samples of cells from brain, adipose tissue, muscle, pancreas, and liver from humans, mice, rats, pigs, 
and dogs. 
91 
 
Lastly, WIN significantly reduced the export of VLDL in our cell model. There is, however no report in 
literature about cannabinoids affecting this pathway. 
Given all these points, it implies that WIN55, as a potent CB1 agonist, induces hepatic steatosis through many 
individual effects. Together with our study, it seems that CB1 activation leads to the observed lipid 
accumulation in hepatocytes by decreasing FA oxidation, upregulation of lipid synthesis, and a decrease of TG 
excretion. 
3.3.4 Mechanisms of Tolcapone and Entacapone 
Tolcapone and entacapone are two valuable drugs for the treatment of Parkinson disease. Since tolcapone, and 
not entacapone, was associated with rare 297, but severe, hepatotoxicity, it has been the focus of numerous 
studies to elucidate its mechanism of toxicity. After reaching the market in 1997, it was shown early on that 
tolcapone is a mitochondrial toxicant.  
Initial investigations by a finnish group reveiled the strong mitochondrial uncoupling potential of tolcapone in 
vitro and in vivo 206-208,298,299. These thorough studies showed tolcapone to be even more potent than the model-
uncoupler 2,4-dinitrophenol and produced corresponding adverse effects, such as swollen mitochondria with 
loss of cristae, elevation of body temperature, increased metabolic rate, diminished ATP/ADP ratio, and thus 
fast onset of rigor mortis. Entacapone, structurally very similar to tolcapone, did also show uncoupling 
potential, however, at higher concentrations than tolcapone. Albeit, it was consistently shown that entacapone 
was safe in even high, but still pharmacologically relevant doses. This trend pervades through all studies 
comparing tolcapone and entacapone, thus in the following sections only consequences of tolcapone treatment 
will be discussed. The discrepancies of the toxic effects of the two drugs will, however, be still discussed at 
the end. 
In agreemant with the finnish group, our study could also show the uncoupling potential of tolcapone, showing 
a direct, protonophoric effect of the drug. The effective uncoupling concentration, however, was higher in our 
studies, explainable by the presence of bovine serum albumin in the respiration medium and the high protein 
binding of tolcapone (99% 206), while Haasio et al. did not have additional protein in their respiration medium.  
We observed an increase in ROS formation after treatment with tolcapone, which is in agreement with the 
finding in literature that tolcapone enhances ROS formation and drastically reduces the antioxidant GSH 300. 
This is somewhat surprising, as nitrocatecholamines, specifically also tolcapone, have intrinsic antioxidant 
properties 301, and it is also postulated that mitochondrial uncoupling reduces the formation of ROS 302. It is 
well-known that inhibition of the respiratory chain is an important mechanism for the production of ROS. In a 
capture compound mass spectrometry study, it was reveiled that tolcapone binds to proteins of the ETC 211. 
We therefore studied the inhibition of individual complexes, which can be challenging, when inhibition and 
uncoupling occurs concominantly. In order to exclude the effects of uncoupling, we spectrophotometrically 
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measured the activity of Complex I – IV in previously frozen mitochondrial isolations, which abolishes the 
integrity of the mitochondrial membrane. Indeed, we found tolcapone to inhibit Complexes I, II, and IV and 
were the first to show this bivalent effect, effectively explaining the ROS accumulation. Additionally, 
tolcapone was reported to induce oxidative stress through its amine- and acetylamine metabolites, which can 
be bioactivated to the o-quinone or quinone-imine form by CYPs 3A4, 2E1, and 1A2, exerting toxicity similar 
to the well-known paracetmaol-NAPQI mechanism 303. We, however, could not observe increased toxicity 
after induction of said enzymes in our cell model. 
Important for our motivation to study tolcapone was the finding of microvesicular steatosis in a patient who 
delevoped tolcapone-related fulminant hepatitis 209. Considering that induction of hepatic steatosis requires 
more than one “hit”, according to the multiple hit theory, it seemed logical to look for an additional mechanism 
to the harsh effects of tolcapone on the oxphos pathway. Furthermore, the capture compound mass 
spectrometry study also showed the binding of tolcapone to enzymes of the FA oxidation pathways 211. This 
study by Fisher et al. prooved itself once again, as we found β-oxidation inhibition in HepaRG cells on the 
level of FA activation and long-chain acyl-CoA dehydrogense. These inhbitions are also represented in the 
acylcarnitine profile of tolcapone treated HepaRG cells, where we saw a decrease in medium-chain 
acylcarnitines and an increase in long-chain acylcarnitines, consistent with a inhibition of overall acylcarnitine 
formation, as seen with triacsin C, the model-ACSL inhibitor, with a simultanious accumulation of long-chain 
acylcarnitines because of the inhibition of long-chain acyl-CoA dehydrogenase. 3-oxo-palmitoylcarnitine was 
increased as well, which was also predicted from the study of Fisher et al. 211, reporting tolcapone binding to 
the 3-keto-acyl-CoA thiolase. Furthermore, this capture compound mass spectrometry study also implemented 
one of the multiple ACSLs, namely ACSL1, in the tolcapone mediated effects, which we also could show with 
the decreased content of this enzyme in our cells. Lastly, Fisher et al. also identified one more enzyme of the 
mitochondrial β-oxidation pathway, the enoyl-CoA hydratase, which we, however, did not investigate. 
In our study, we found even more negative effects, fueling the progression of hepatic steatosis, as we saw an 
upregulation of genes related to the uptake of FAs (CD36 and FATP5), as well as a decreased excretion of 
VLDL, resulting from decreased synthesis of ApoB100. It could be, that the upregulation of CD36 and FATP5 
is a compensatory mechanism to the inhibiton of ACSL1 (or others), as these FA transporters also exert FA 
activation, besides their cellular uptake 304,305. Furthermore, it is also reported in literature that tolcapone can 
inhibit the export of bile acids in hepatocytes 306.  This finding is of importance, as it is known that the 
accumulation of bile acids can have multiple inhibitory effects on the energy metabolism in hepatocytes. 
Studies by Krähenbühl et al. have shown that accumulating lipophilic bile acids exert toxicity on mitochondria, 
such as inhibition of respiratory complexes 154, decrease of antioxidative capacity 307, and inhibition of FA 
oxidation 65,308. 
Lastly, the question remains why entacapone, structurally very similar, as well as in its molecular effects, does 
not show clinical toxicity to a similar extent like tolcapone. After all, entacapone showed many of the effects 
like tolcapone. It uncouples mitochondria, increases lipid accumulation in HepG2 cells, is also reported to 
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inhibit bile acid excretion 306, depresses medium-chain acylcarnitines with an increase in palmitoylcarnitine, 
and inhibits Complex I and IV. In the capture compound mass spectrometry study, it was also shown to bind 
to similar proteins, as tolcapone does 211. Suprisingly, however, entacapone is consistently shown to be untoxic 
214, also until high concentrations 208. Toxic effects of entacapone always occur at significant higher doses as 
with tolcapone. Since pharmacological concentrations in plasma, after ingestion of the normal dose of 200 mg 
of either drug, reach maximal concentrations of 21 µM and 6 µM for tolcapone and entacapone, respectively202, 
the almost non-existent hepatotoxicity of entacapone in patients makes sense. Furthermore, entacapone has a 
higher clearance and is less lipophilic than tolcapone, thus less likely to accumulate in membranes. 
As shown above, tolcapone has manifold effects on hepatic energy metabolism, explaining the induction of 
microvesicular steatosis, as seen in patients. Taken together, the hits leading to this adverse reactions are 
mitochondrial dysfunction on the level of respiration and FA oxidation, as well as decreased TG excretion. 
The disturbed energy production is nicely visible by the increase of lactate in our treated cells, showing a shift 
to glycolysis to restore the decreased ATP production by mitochondria. Furthermore, the increase in ROS with 
concominant decrease in antioxidative capacity, also shown by decrease in SOD1 and SOD2, further signifies 
the toxic insult of tolcapone on the liver. Moreover, the importance of FA oxidation inhibition for the toxic 
effect of the drug was shown by the fact that tolcapone decreases energy production of cells even in the absence 
of the influence on the ETC309, as well as underlying mitochondrial dysfunction was shown to be a 
susceptebility factor for tolcapone-induced liver injury 310. All the effects, discussed above, decisively explain 
the finding of necrosis, rather than apoptosis, which would rely on ATP, of which the cell is devoided, as well 
as the induction of steatosis and shed new light on the mechanism of tolcapone-associated DILI. 
3.3 Concluding Remarks and Outlook 
During our studies on the mechanisms of drug-induced hepatic steatosis, we applied the acylcarnitine method, 
as well as old and well-known methods, to assess inhibitions of mitochondrial β-oxidation. We could 
constantly show that the results of the acylcarnitine pattern were in agreement with the findings obtained with 
established, direct determinations of enzyme activities. Using the acylcarnitine types, included in our 
measurement, we could make clear predictions about inhibition of import or activation, general chain-length 
specificity of FA breakdown, acetyl-CoA content, as well as long-chain β-keto thiolase inhibition. 
Unquestionably, this gave us valuable insight into the mechanism of the drugs included in our studies, however, 
not to the full extent possible. The breakdown of FAs involves several more enzymes, worth including in the 
method. Therefore, it would be of value to supplement the LC-MS/MS method with intermediates, such as 
enoyl-carnitines and 3-hydroxyacyl-carnitines. Furthermore, of the aforementioned intermediates, as well as 
of the 3-ketoacyl-carnitine, of which we only have the C16 form, additional determination of short- and 
medium-chain forms would be of value. 
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This, however, would require specific inhibitors of corresponding enzymes, which is, to the best of our 
knowledge, not existing for all of them. Indeed, certain inhibitors, such as MCPA, could be altered to be more 
specific for different FA chain-lengths. In the case of MCPA this was shown by synthesis of C6-MCPA 
(Fig. 25a), which provided an inhibitor more specific to long-chain acyl-CoA dehydrogenase 168. The same 
approach could be used for generating C12-MCPA (Fig. 25b), which should be specific only for the long-
chain acyl-CoA dehydrogenase. Likewise, increasing the chain-length of 4-bromocrotonic acid to 
16-bromohexadec-2-enoic acid (Fig. 25c) for specific inhibition of the long-chain β-keto thiolase could be 
possible. In the same fashion, other brominated FAs and FA breakdown intermediate analogs have been shown 
to irreversibly inhibit enzymes in the β-oxidation, by forming covalent adducts to a lysine, cysteine, or serine 
residue within the active site 311. The specificity of these inhibitors to one enzyme, however, remains 
questionable, considering the studies with 4-bromocrotonic acid. Also inhibitors for the enoyl-CoA 
hydratase312 (Fig. 25d), short-chain-313 (Fig. 25e), and long-chain 3-hydroxyacyl-CoA dehydrogenase314 
(Fig. 25f) have been identified. Clear data on their specificity, however, is lacking.  
 
We fed our cells with palmitic- and oleic acid, for studying the effects and consequences of the inhibitors we 
used, with attention to enzymes involved in metabolism of saturated FAs. Inclusion of branched-chain, 
multiple unsaturated, or very-long-chain FAs and inhibitors of enzymes involved in their metabolism, 
therefore, could also be considered. 
As illustrated above, the acylcarnitine method has a great potential to be adapted to various domains of FA 
metabolism research. Due to the possibility to link the assay with multiple others, using various well-plate 
systems, as well as its fast and simple workup and analysis, this method represents a relevant possibility to use 
for investigators. In our case, especially the conjunction with lipid accumulation, cell viability/apoptosis, and 
VLDL export would represent an improved and streamlined approach to determinations, which are already 
established in our laboratory. This would be possible by using the supernatants of cells for acylcarnitine 
Fig. 25. Chemical structures of the proposed specific inhibitors of fatty acid oxidation. a) C6-MCPA, 
b) C12-MCPA, c) 16-bromohexadec-2-enoic acid, d) 5,6-dichloro7,7,7-trifluoro-4-thia-5-heptenoyl-
CoA, e) AG18051 and f) benzotript.  
a) 
c) 
d) 
b) 
e) f) 
95 
 
analysis and determination of excreted VLDL, then using trypsinized cells for simultaneous and semi-
automatic analysis by flow cytometric of lipid accumulation with a BODIPY dye, as well as determination of 
cell viability and apoptosis with the AnnexinV/PI staining, in 96-well format. Particularly, this would reduce 
time and costs for the screening of drugs with possible steatogenic effects, which would also serve the need of 
the industry of preclinical high-throughput screening methods for the early detection of possible adverse effects 
of drug candidates. 
 
In conclusion, we could show the value and applicability of the analysis of acylcarnitine pattern in our work. 
Together with an additional battery of assessments, we were successful in confirming, as well as in shedding 
new light on the molecular mechanisms of drug-induced steatosis of several compounds. Therefore, the 
acylcarnitine method, as well as our findings, will hopefully improve the investigation and understanding of 
adverse reactions on the liver for academia as well as for the industry, ultimately improving the work of 
clinicians and more importantly the life of patients. 
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